Methods for promoting immune cell proliferation
Patent Information
- Application Number
- JP2020550874
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-03-26
- Filing Date
- 2019-03-25
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The proliferative capacity of CAR-expressing immune cells in Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) is limited, which restricts its efficacy in treating tumors like acute leukemia and non-Hodgkin's lymphoma.
Enhancing the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells to promote proliferation, increase cytokine release, inhibit differentiation, and enhance tumor-killing ability, while preventing tumor recurrence.
The method significantly increases the effectiveness of immune cells in treating tumors by enhancing proliferation, memory cell production, cytokine release, and tumor-killing capacity, thereby improving treatment outcomes and reducing recurrence.
Smart Images

Figure 00000049_0000 
Figure 00000049_0001 
Figure 00000049_0002
Abstract
Description
Technical Field
[0001] This application relates to a method for promoting the proliferation of immune cells. In particular, this application is a method capable of increasing the expression level of low-density lipoprotein receptor-related protein or a fragment thereof in the immune cells.
Background Art
[0002] Chimeric antigen receptor T-cell immunotherapy (CAR-T) enhances the specific killing of tumors by T cells by expressing a chimeric antigen receptor (CAR) and modifying T cells by genetic engineering means so as to recognize an antibody of a tumor cell surface antigen. CAR generally includes a single-chain variable region domain (scFv) that specifically recognizes a tumor-associated antigen (TAA), a hinge region, a transmembrane region, and an intracellular signaling region.
[0003] In recent years, although CAR-T immunotherapy has shown obvious effectiveness in the treatment of acute leukemia and non-Hodgkin lymphoma, there is a limit to the proliferation ability of immune cells expressing CAR.
Summary of the Invention
[0004] This application provides genetically modified immune cells and a method for promoting immune cell proliferation. The method according to this application can increase the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the immune cells. The method according to this application can further promote the production of memory immune cells. The method according to this application can further suppress immune cell differentiation. The method according to this application can further increase the release of cytokines by immune cells. The method according to this application can further increase the tumor-killing ability of immune cells. Furthermore, the method according to this application can prevent tumor recurrence in subjects. This application further provides a method for treating tumors in subjects where it is necessary. This application further provides a composition comprising the aforementioned genetically modified immune cells, and uses of the aforementioned genetically modified immune cells and composition in the preparation of pharmaceuticals. This application further provides a method for preparing the aforementioned genetically modified immune cells.
[0005] On the other hand, the present invention provides a method for promoting immune cell proliferation, which includes the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the aforementioned immune cells.
[0006] On the other hand, the present invention provides a method for promoting memory immune cell production, which includes the step of promoting the differentiation of the aforementioned immune cells into memory immune cells by increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.
[0007] On the other hand, the present invention provides a method for suppressing immune cell differentiation, which includes the step of suppressing the differentiation of the aforementioned immune cells into differentiated immune cells by increasing the expression level of the aforementioned low-density lipoprotein receptor-related protein or a fragment thereof in the aforementioned immune cells.
[0008] On the other hand, the present invention provides a method for increasing cytokine release by immune cells, which includes the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the aforementioned immune cells.
[0009] In one embodiment, the cytokines described above consist of interleukins, interferons, and / or tumor necrosis factor. In another embodiment, the cytokines described above consist of IL-2, IL4, IL6, IL7, IL10, IL12, TNF-α, and / or IFNγ.
[0010] On the other hand, the present invention provides a method for increasing the tumor-killing ability of immune cells, which includes the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the aforementioned immune cells.
[0011] On the other hand, the present invention provides a method for preventing tumor recurrence in a subject who is susceptible to tumors, comprising administering immune cells in which the expression level of low-density lipoprotein receptor-related protein or a fragment thereof is enhanced.
[0012] On the other hand, the present invention provides a method for treating a tumor in a subject, which requires the subject to be administered immune cells in which the expression level of low-density lipoprotein receptor-related protein or a fragment thereof is increased.
[0013] In one embodiment, the aforementioned tumors are selected from liver cancer, lung cancer, leukemia, and mesothelioma.
[0014] In one embodiment, the method described above includes an in vivo method and an in vitro method.
[0015] In one embodiment, the aforementioned immune cells include lymphocytes. In one embodiment, the aforementioned immune cells include T cells. In one embodiment, the aforementioned T cells include memory stem cell-like T cells (TSCMs) and / or central memory T cells (TCMs). In one embodiment, the aforementioned TSCMs are CCR7 + and / or CD62L + In one embodiment, the aforementioned TSCM further includes CD45RA + Or CD45RA- 、 CD45RO + or CD45RO - 、 CD27 + 、 CD28 + 、 CD127 + 、 CD122 + 、 CD3 + 、 CD4 + and CD8 + and has one or more characteristics selected from the group consisting of.
[0016] In certain embodiments, the immune cells described above contain genetically modified immune cells that express a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In certain embodiments, the genetically modified immune cells described above contain genetically modified T cells.
[0017] In certain embodiments, the CAR described above contains an intracellular domain composed of a signaling domain and / or a co-stimulatory domain.
[0018] In certain embodiments, the signaling domain described above includes a portion selected from the group consisting of the CD3ζ signaling domain, the CD3δ signaling domain, and the CD3ε signaling domain. In certain embodiments, the signaling domain described above contains the amino acid sequence represented by SEQ ID NO: 18 or an amino acid sequence having at least 80% homology thereto. In certain embodiments, the nucleic acid molecule encoding the signaling domain described above contains the nucleic acid sequence represented by SEQ ID NO:17 or a nucleic acid sequence having at least 80% homology thereto.
[0019] In one embodiment, the aforementioned co-stimulatory domain includes a portion selected from the group consisting of the CD27 co-stimulatory domain, the CD28 co-stimulatory domain, and the 4-1BB co-stimulatory domain. In one embodiment, the aforementioned co-stimulatory domain contains an amino acid sequence represented by either SEQ ID NO:14 or SEQ ID NO:16, or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned co-stimulatory domain contains a nucleic acid sequence represented by either SEQ ID NO:13 or SEQ ID NO:15, or a nucleic acid sequence having at least 80% homology thereto.
[0020] In one embodiment, the aforementioned CAR is composed of a hinge region. In one embodiment, the aforementioned hinge region includes a portion selected from the group consisting of the hinge region of IgG4, the hinge region of IgG1, and the hinge region of CD8. In one embodiment, the aforementioned hinge region contains an amino acid sequence represented by SEQ ID NO: 31. In one embodiment, the nucleic acid molecule encoding the aforementioned hinge region contains a nucleotide sequence represented by SEQ ID NO: 32.
[0021] In one embodiment, the aforementioned CAR is composed of a transmembrane region. In one embodiment, the aforementioned transmembrane region includes a portion selected from the group consisting of the CD8 transmembrane region, the CD28 transmembrane region, and the CD24 transmembrane region. In one embodiment, the aforementioned transmembrane region contains an amino acid sequence represented by SEQ ID NO: 33. In one embodiment, the nucleic acid molecule encoding the aforementioned transmembrane region contains a nucleotide sequence represented by SEQ ID NO: 34.
[0022] In one embodiment, the aforementioned CAR is composed of a target-directing portion. In one embodiment, the aforementioned target-directing portion includes an ScFv.
[0023] In one embodiment, the aforementioned target-directed moiety specifically binds to and / or recognizes a tumor antigen. In another embodiment, the aforementioned target-directed moiety specifically binds to and / or recognizes a target selected from the group consisting of B lymphocyte surface antigens, TNF family members, HER family members, and GPC family members. In yet another embodiment, the aforementioned target-directed moiety specifically binds to and / or recognizes a target selected from the group consisting of CD19, BCMA, HER2, Mesothelin, and GPC3.
[0024] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes CD19, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 46 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 47 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 48 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 50 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 43 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 44 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 45 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 49 or an amino acid sequence having at least 80% homology thereto.
[0025] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes BCMA, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 54 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 55 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 56 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 58 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 51 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 52 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 53 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 57 or an amino acid sequence having at least 80% homology thereto.
[0026] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes HER2, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 70 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 71 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 72 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 74 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 67 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 68 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 69 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 73 or an amino acid sequence having at least 80% homology thereto.
[0027] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes mesothelin, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 62 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 63 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 64 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 66 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 59 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 60 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 61 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 65 or an amino acid sequence having at least 80% homology thereto.
[0028] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes GPC3, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 38 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 39 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 40 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 42 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 35 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 36 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 41 or an amino acid sequence having at least 80% homology thereto.
[0029] In one embodiment, the aforementioned target-directed portion contains an amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, and 10, or an amino acid sequence having at least 80% homology thereto. In another embodiment, the nucleic acid molecule encoding the aforementioned target-directed portion contains a nucleic acid sequence represented by SEQ ID NO: 1, 3, 5, 7, and 9, or an amino acid sequence having at least 80% homology thereto.
[0030] In one embodiment, the method described above further includes peripheral blood mononuclear cells (PBMCs) and CD3 +T lymphocytes, CD8 + T lymphocytes, CD4 + The process includes the step of obtaining T lymphocytes or regulatory T cells by isolating them.
[0031] In one embodiment, the method described above further includes adding one or more T cell stimulating factors to the isolated PBMCs. In one embodiment, the T cell stimulating factors are selected from the group consisting of B lymphocyte surface antigen antibodies, TNF antibodies, intracellular polyesters, and antibiotics. In one embodiment, the T cell stimulating factors are selected from the group consisting of CD3 antibodies, CD28 antibodies, 4-1BB antibodies, CD80 antibodies, CD86 antibodies, PHA, PMA, and ionomycin.
[0032] In one embodiment, the aforementioned T cell stimulating factor includes a CD3 antibody at a concentration of 1 to 10,000 ng / mL. In another embodiment, the aforementioned T cell stimulating factor includes a CD28 antibody at a concentration of 1 to 10,000 ng / mL.
[0033] In one embodiment, the method described above further includes adding one or more cytokine agents to the isolated PBMCs described above.
[0034] In one embodiment, the cytokine agent described above contains interleukin.
[0035] In one embodiment, the aforementioned interleukin contains one or more types selected from the group consisting of IL2, IL21, IL7, and IL15. In one embodiment, the aforementioned interleukin contains IL2 at a concentration of 0.1 to 10000 U / mL. In one embodiment, the aforementioned interleukin contains IL21 at a concentration of 0.01 to 1000 ng / mL. In one embodiment, the aforementioned interleukin contains IL7 at a concentration of 0.01 to 1000 ng / mL. In one embodiment, the aforementioned interleukin contains IL15 at a concentration of 0.01 to 1000 ng / mL.
[0036] In one embodiment, the aforementioned low-density lipoprotein receptor-related protein contains one or more selected from the group of low-density lipoprotein receptor-related proteins 1 to 12 and their functional fragments. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein or its fragment is of human origin.
[0037] In one embodiment, the aforementioned functional fragment includes a fragment or a truncated form of the aforementioned low-density lipoprotein receptor-related protein having the aforementioned low-density lipoprotein receptor-related protein activity. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein includes low-density lipoprotein receptor-related protein 6 and its truncated form, and / or low-density lipoprotein receptor-related protein 5 and its truncated form. In one embodiment, the truncated form of the aforementioned low-density lipoprotein receptor-related protein 6 includes the intracellular region of the aforementioned low-density lipoprotein receptor-related protein 6, and / or the truncated form of the aforementioned low-density lipoprotein receptor-related protein 5 includes the intracellular region having the aforementioned low-density lipoprotein receptor-related protein 5. In one embodiment, the truncated form of the aforementioned low-density lipoprotein receptor-related protein 6 comprises the transmembrane region of the aforementioned low-density lipoprotein receptor-related protein 6 and the LDLR domain of the aforementioned low-density lipoprotein receptor-related protein 6, and / or the truncated form of the aforementioned low-density lipoprotein receptor-related protein 5 comprises the transmembrane region having the aforementioned low-density lipoprotein receptor-related protein 5 and the LDLR domain of the aforementioned low-density lipoprotein receptor-related protein 5. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein or fragment thereof contains an amino acid sequence represented by any of SEQ ID NO: 22, 24, 26, and 28 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned low-density lipoprotein receptor-related protein or fragment thereof contains a nucleic acid sequence represented by any of SEQ ID NO: 21, 23, 25, and 27 or an amino acid sequence having at least 80% homology thereto.
[0038] On the other hand, the present invention provides genetically modified immune cells that increase the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells through genetic modification.
[0039] In one embodiment, the genetically modified immune cells described above include lymphocytes. In one embodiment, the genetically modified immune cells described above include genetically modified T cells. In one embodiment, the genetically modified immune cells described above include genetically modified memory stem cell-like T cells (TSCMs) and / or genetically modified central memory T cells (TCMs). In one embodiment, the TSCMs described above are CCR7 + and / or CD62L + In one embodiment, the aforementioned TSCM further includes CD45RA + Or CD45RA - CD45RO + Or CD45RO - CD27 + CD28 + CD127 + CD122 + CD3 + CD4 + and CD8 + It possesses one or more characteristics selected from the group.
[0040] In one embodiment, the aforementioned immune cells include genetically modified immune cells that express a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
[0041] In one embodiment, the aforementioned CAR includes an intracellular domain comprising a signaling domain and / or a co-stimulatory domain. In one embodiment, the aforementioned signaling domain includes a portion selected from the group consisting of a CD3ζ signaling domain, a CD3δ signaling domain, and a CD3ε signaling domain. In one embodiment, the aforementioned signaling domain contains an amino acid sequence represented by SEQ ID NO: 18. In one embodiment, the nucleic acid molecule encoding the aforementioned signaling domain contains a nucleic acid sequence represented by SEQ ID NO: 17 or a nucleic acid sequence having at least 80% homology thereto.
[0042] In one embodiment, the aforementioned co-stimulatory domain includes a portion selected from the group consisting of the CD27 co-stimulatory domain, the CD28 co-stimulatory domain, and the 4-1BB co-stimulatory domain. In one embodiment, the aforementioned co-stimulatory domain contains an amino acid sequence represented by either SEQ ID NO:14 or SEQ ID NO:16, or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned co-stimulatory domain contains a nucleic acid sequence represented by either SEQ ID NO:13 or SEQ ID NO:15, or a nucleic acid sequence having at least 80% homology thereto.
[0043] In one embodiment, the aforementioned CAR is composed of a hinge region. In one embodiment, the aforementioned hinge region includes a portion selected from the group consisting of the hinge region of IgG4, the hinge region of IgG1, and the hinge region of CD8. In one embodiment, the aforementioned hinge region contains the amino acid sequence represented by SEQ ID NO: 31 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned hinge region contains the nucleic acid sequence represented by SEQ ID NO: 32 or an amino acid sequence having at least 80% homology thereto.
[0044] In one embodiment, the aforementioned CAR is composed of a transmembrane region. In one embodiment, the aforementioned transmembrane region includes a portion selected from the group consisting of the CD8 transmembrane region, the CD28 transmembrane region, and the CD24 transmembrane region. In one embodiment, the aforementioned transmembrane region contains an amino acid sequence represented by SEQ ID NO: 33 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned transmembrane region contains a nucleic acid sequence represented by SEQ ID NO: 34 or a nucleic acid sequence having at least 80% homology thereto.
[0045] In one embodiment, the aforementioned CAR is composed of a target-directed portion. In one embodiment, the aforementioned target-directed portion contains ScFv. In one embodiment, the aforementioned target-directed portion specifically binds to and / or recognizes a tumor antigen. In one embodiment, the aforementioned target-directed portion specifically binds to and / or recognizes a target selected from the group consisting of B lymphocyte surface antigens, TNF family members, HER family members, and GPC family members. In one embodiment, the aforementioned target-directed portion specifically binds to and / or recognizes a target selected from the group consisting of CD19, BCMA, HER2, Mesothelin, and GPC3.
[0046] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes CD19, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 46 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 47 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 48 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 50 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 43 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 44 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 45 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 49 or an amino acid sequence having at least 80% homology thereto.
[0047] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes BCMA, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 54 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 55 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 56 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 58 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 51 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 52 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 53 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 57 or an amino acid sequence having at least 80% homology thereto.
[0048] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes HER2, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 70 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 71 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 72 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 74 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 67 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 68 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 69 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 73 or an amino acid sequence having at least 80% homology thereto.
[0049] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes mesothelin, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 62 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 63 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 64 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 66 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 59 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 60 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 61 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 65 or an amino acid sequence having at least 80% homology thereto.
[0050] In one embodiment, the aforementioned target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes GPC3, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 38 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 39 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 40 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the aforementioned light chain variable region contains an amino acid sequence represented by SEQ ID NO: 42 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the antibody or its antigen-binding fragment includes a heavy chain variable region comprising: HCDR1 containing an amino acid sequence represented by SEQ ID NO: 35 or an amino acid sequence having at least 80% homology thereto; HCDR2 containing an amino acid sequence represented by SEQ ID NO: 36 or an amino acid sequence having at least 80% homology thereto; and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the heavy chain variable region includes an amino acid sequence represented by SEQ ID NO: 41 or an amino acid sequence having at least 80% homology thereto.
[0051] In one embodiment, the aforementioned target-directed portion contains an amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, and 10, or an amino acid sequence having at least 80% homology thereto. In another embodiment, the nucleic acid molecule encoding the aforementioned target-directed portion contains a nucleic acid sequence represented by SEQ ID NO: 1, 3, 5, 7, and 9, or a nucleic acid sequence having at least 80% homology thereto.
[0052] In one embodiment, the aforementioned low-density lipoprotein receptor-related protein contains one or more selected from the group of low-density lipoprotein receptor-related proteins 1 to 12 and their functional fragments. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein or its fragment is of human origin.
[0053] In one embodiment, the aforementioned functional fragment includes a fragment or a truncated form of the aforementioned low-density lipoprotein receptor-related protein having the aforementioned low-density lipoprotein receptor-related protein activity. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein includes low-density lipoprotein receptor-related protein 6 and its truncated form, and / or low-density lipoprotein receptor-related protein 5 and its truncated form. In one embodiment, the truncated form of the aforementioned low-density lipoprotein receptor-related protein 6 includes the intracellular domain of the aforementioned low-density lipoprotein receptor-related protein 6, and / or the truncated form of the aforementioned low-density lipoprotein receptor-related protein 5 includes the intracellular domain of the aforementioned low-density lipoprotein receptor-related protein 5. In one embodiment, the truncated form of the aforementioned low-density lipoprotein receptor-related protein 6 comprises the transmembrane region of the aforementioned low-density lipoprotein receptor-related protein 6 and / or the truncated form of the aforementioned low-density lipoprotein receptor-related protein 5 comprises the transmembrane region of the aforementioned low-density lipoprotein receptor-related protein 5 the LDLR domain of the aforementioned low-density lipoprotein receptor-related protein 5. In one embodiment, the aforementioned low-density lipoprotein receptor-related protein or fragment thereof contains an amino acid sequence represented by any of SEQ ID NO: 22, 24, 26, and 28 or an amino acid sequence having at least 80% homology thereto. In one embodiment, the nucleic acid molecule encoding the aforementioned low-density lipoprotein receptor-related protein or fragment thereof contains a nucleic acid sequence represented by any of SEQ ID NO: 21, 23, 25, and 27 or a nucleic acid sequence having at least 80% homology thereto.
[0054] On the other hand, the present application provides a composition containing the aforementioned genetically modified immune cells.
[0055] In one embodiment, the aforementioned composition further optionally includes a pharmaceutically acceptable vector.
[0056] On the other hand, this application provides the use of the aforementioned genetically modified cells and / or compositions in the preparation of pharmaceuticals for the treatment and / or prevention of tumors.
[0057] In one embodiment, the aforementioned tumors are selected from liver cancer, lung cancer, leukemia, and mesothelioma.
[0058] On the other hand, the present invention provides a method for preparing the aforementioned composition, which includes the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the aforementioned genetically modified immune cells.
[0059] In one embodiment, the method described above includes the step of introducing a vector that increases the expression level of the low-density lipoprotein receptor-related protein or a fragment thereof into the genetically modified immune cells described above. In one embodiment, the vector described above is selected from the group consisting of retroviral vectors, lentiviral vectors, and transposon plasmids.
[0060] In one embodiment, the aforementioned low-density lipoprotein receptor-related protein or fragment thereof contains an amino acid sequence represented by SEQ ID NO: 22, 24, 26, and 28, or an amino acid sequence having at least 80% homology thereto.
[0061] In one embodiment, the genetically modified immune cells described above include lymphocytes. In one embodiment, the genetically modified immune cells described above express chimeric antigen receptors (CARs). In one embodiment, the method described above includes the step of activating the genetically modified immune cells described above, which consists of isolation and administration of T cell culture medium to the isolated genetically modified immune cells.
[0062] In one embodiment, the aforementioned T cell medium contains one or more types selected from the group consisting of DMEM medium, 1640 medium, MEM medium, and X-VIVO medium.
[0063] In one embodiment, the method described above further includes administering a T cell stimulating factor to the genetically modified immune cells described above.
[0064] Those skilled in the art will readily grasp other aspects and advantages of this disclosure from the detailed description that follows. The detailed description below only describes embodiments as examples of this disclosure. Those skilled in the art may modify the specific embodiments disclosed by the details of this disclosure, as long as they do not deviate from the spirit or scope of the invention. Accordingly, the drawings and descriptions in the specification are illustrative and not limiting to the invention. [Brief explanation of the drawing]
[0065] The specific features of the present invention are as shown in the attached claims. The features and advantages of the present invention will be more clearly understood by referring to the exemplary embodiments and drawings described in detail below. The drawings will be described in general terms as follows.
[0066] Figure 1 shows a schematic diagram of the CAR structure described above in the lentivirus according to the present invention.
[0067] Figure 2 shows the results of promoting memory immune cell production using genetically modified immune cells according to the present invention.
[0068] Figure 3 shows the results of suppressing immune cell differentiation using genetically modified immune cells according to the present invention.
[0069] Figure 4 shows the results of promoting immune cell proliferation according to the present invention by low-density lipoprotein receptor-related protein or a fragment thereof in immune cells.
[0070] Figures 5A to 5B show the results of increasing cytokine release using genetically modified immune cells according to the present invention.
[0071] Figure 6 shows the antitumor effect of genetically modified immune cells according to the present invention.
[0072] Figure 7 shows the effect of preventing tumor recurrence using genetically modified immune cells according to the present invention. [Modes for carrying out the invention]
[0073] The embodiments of the present invention will be described below with reference to specific examples, but those skilled in the art will be able to easily grasp other advantages and effects of the present invention from the information disclosed herein.
[0074] In the present invention, the term "immune cells" generally refers to cells that are involved in or related to an immune response. These immune cells may include lymphocytes and various types of phagocytes. These immune cells may include both naturally occurring and genetically modified cells. In the present invention, these genetically modified immune cells may express chimeric antigen receptors (CARs). Here, the lymphocytes may include T lymphocytes and B lymphocytes. In the present invention, these immune cells may include T cells.
[0075] In the present invention, the term "memory immune cells" generally refers to immune cells that possess immunological memory. This immunological memory is characterized by the ability to specifically recognize and respond to a particular antigen, and then, upon encountering the same antigen again, to exert a rapid and effective immune response. In the present invention, these memory immune cells may include memory T cells. These memory T cells can be divided into memory stem cell-like T cells (TSCMs) and central memory T cells (TCMs).
[0076] In the present invention, the term differentiated immune cells generally refers to immune cells that have a certain degree of differentiation. For example, the differentiated immune cells described above may be T cells that have a certain degree of differentiation. In the present invention, the differentiated immune cells described above are obtained by differentiating the immune cells described above to a certain extent through culture. For example, the differentiated immune cells described above may include regulatory T cells (Tregs).
[0077] In this invention, the term "regulatory T cell" (Treg) usually refers to a type of lymphocyte that negatively regulates the immune response of the body. The molecular labeling of the above regulatory T cells is the transcription factor Foxp3 + Or CD127 - It may be so. In the present invention, the regulatory T cells may be divided into naturally occurring and induced production. Here, the naturally occurring ones are CD4 + CD25 + These are cells, and those produced by induction are T R 1 cell and T H It has 3 cells.
[0078] In this invention, the term "subject susceptible to tumors" generally refers to a subject whose probability of developing a tumor is higher than that of a general subject. For example, a subject susceptible to tumors may be one who, even if cured of a tumor, still faces risks such as metastasis and recurrence. A subject susceptible to tumors may also be diagnosed with risk factors for developing tumors. For example, these risk factors may include several gene mutations (deletions, additions, or substitutions) that have been shown to correlate with tumors. In this invention, a subject susceptible to tumors may also be one who has been exposed to a carcinogenic environment for a long period of time. For example, this carcinogenic environment may include high levels of radiation or high concentrations of carcinogenic substances.
[0079] In the present invention, the term "gene modification" generally refers to modifications or alterations that occur at the gene structure level. For example, the above gene modification may be an alteration at the gene level, transcriptional level, and / or translational level. Alternatively, for example, the above gene modification may include any alteration of the genetic characteristics in an organism (such as its tissues, cells, DNA, mRNA, or proteins or fragments thereof). The above gene modification may include enabling the expression of a predetermined protein or fragment in the organism. For example, the above gene modification may include providing the organism with a vector capable of expressing the predetermined protein or fragment.
[0080] In this invention, the term T cell, also referred to as a T lymphocyte, is a subtype of white cell that primarily plays a role in cell-mediated immunity. T cells are distinguished from other lymphocytes, such as B cells and natural killer cells, by T cell receptors present on their cell surface. In this invention, the above-mentioned T cells may include memory stem cell-like T cells (TSCMs) and central memory T cells (TCMs).
[0081] In this invention, the term memory stem cell-like T cells (TSCMs) generally refers to cells that are in the early stages of differentiation of memory T cells, possess stem cell characteristics, and have strong pluripotency. When TSCM cells respond to antigen stimulation, they differentiate into central memory T cells (TCMs), effector memory T cells (TEMs), and effector T cells (TEFs).
[0082] In this invention, the term "central memory T cells" (TCM) usually refers to T cells that possess long-term memory, which are produced after naive T cells are activated by an antigen. The biomarker for the above TCM is CD62L. + and CD45RO + The above-mentioned central memory T cells, upon returning to the lymph nodes due to lymphatic shielding, are simultaneously activated by the antigen.
[0083] In the present invention, the term T cell receptor, also commonly referred to as TCR, usually refers to a molecular structure that enables the specific recognition and binding of antigen peptide-MHC molecules by T cells. The above T cell receptor may exist on the surface of T cells as a complex with CD3 molecules. The above TCR is a heterodimer fixed to the cell membrane, often composed of highly variable α and β subunits via disulfide bonds, and less often composed of γ and δ peptide chains. The above TCR may include a variable region responsible for recognizing polypeptide / MHC complexes, and a constant region located proximal to the cell membrane, with a transmembrane region linked to an intracellular end.
[0084] In the present invention, the term chimeric antigen receptor, also commonly referred to as CAR, typically refers to a fusion protein comprising an extracellular domain capable of binding to an antigen and at least one intracellular domain. In this application, the CAR described above may include an intracellular domain comprising a signaling domain and / or a costimulatory domain. In the present invention, a group of polypeptides in a CAR may be located on the same polypeptide chain (e.g., including a chimeric fusion protein), but they do not have to be contiguous, for example, located on different polypeptide chains. In the present invention, the signal involved in induction is transmitted to the cytoplasm of a T cell via CD3 and zeta chains. In the present invention, the intracellular domain may include one first-level signaling domain (e.g., the major signaling domain of CD3-zeta(ζ)). In one aspect, the cytoplasmic signaling domain may include one or more costimulatory domains induced from at least one costimulatory molecule. For example, the costimulatory domains may be 4-1BB (i.e., CD137), CD27, ICOS, and / or CD28. In the present invention, the CAR may have, for example, a chimeric fusion protein containing an optional leader sequence at its amino terminus (N-ter). Here, the above-mentioned leader sequence may, if necessary, cleave an antigen-binding domain (e.g., ScFv) during cell processing to position the CAR on the cell membrane.
[0085] In the present invention, the term signaling domain usually refers to a signal-transmitting domain located inside a cell. In the present invention, the intracellular signaling domain is capable of transmitting signals within the cell. For example, the intracellular signaling domain described above is the intracellular signaling domain in the chimeric antigen receptor described above. In the present invention, the signaling domain includes a portion selected from the group of CD3ζ, CD3δ, and CD3ε signaling domains.
[0086] In the present invention, the term "co-stimulatory domain" typically refers to a domain in a CAR that crosses the cell membrane, ligates to an intracellular signaling domain, and performs the function of transferring signals. In the present invention, the above-mentioned co-stimulatory domain includes a portion selected from the group consisting of CD27, CD28, and 4-1BB co-stimulatory domains.
[0087] In the present invention, the term hinge region usually refers to the junction region between the antigen-binding domain and the immune cell Fc receptor (FcR)-binding domain. For example, the hinge region may be the region between the heavy chain CHl and the CH2 functional domain in immunoglobulin. In the present invention, the hinge region may be a single region between scFv and the T cell membrane. The hinge region may be derived from IgG1 or IgG4, or from IgD or CD8. In the present invention, the hinge region includes a portion selected from the group consisting of the hinge region of IgG4, the hinge region of IgG1, and the hinge region of CD8.
[0088] In the present invention, the term transmembrane region typically refers to a region composed of dimeric membrane proteins, mainly containing CD3ζ, CD4, CD8, CD28, etc., that can anchor a CAR structure to the T cell membrane, and that links an extracellular antigen-binding domain with an intracellular signaling domain. Different designs of the transmembrane region can affect the expression of the introduced CAR gene. In the present invention, the above-mentioned transmembrane region includes a portion selected from the group consisting of the CD8 transmembrane region, the CD28 transmembrane region, and the CD24 transmembrane region.
[0089] In the present invention, the term single-chain antibody (ScFv) usually refers to an antibody in which the heavy chain variable region and the light chain variable region are linked by a linker. In the present invention, the linker may be a linked peptide.
[0090] In the present invention, the term tumor antigen typically refers to an antigenic substance that is present in or produced by tumor cells and may have the ability to elicit an immune response in a host. For example, a tumor antigen may be a protein, polypeptide, peptide or fragment thereof that constitutes part of a tumor cell and induces tumor-specific cytotoxic T lymphocytes. In some embodiments, the term tumor antigen may further be a biomolecule (e.g., protein, carbohydrate, glycoprotein, etc.) that is exclusively, preferentially, or differentially expressed on cancer cells and / or related to cancer cells, providing a preferential or specific target for cancer. For example, preferential expression may be conventional preferential expression compared to all other cells in the body, or preferential expression in a given region in the body (e.g., within a given organ or tissue). In the present invention, the tumor antigen may be a B lymphocyte surface antigen, a TNF family member, a HER family member, and a GPC family member.
[0091] In the present invention, the term B lymphocyte surface antigen usually refers to antigens produced by B lymphocytes in different stages and present on the surface of B lymphocytes. For example, the above B lymphocyte surface antigens may include CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD38, CD39, and CD40. In the present invention, the B lymphocyte surface antigen may include CD19.
[0092] In the present invention, the term CD19 may refer to the differentiated group 19 protein, which is an antigenic determinant measurable in leukemia progenitor cells. Human CD19 has a UniProt / Swiss-Prot accession number of P15391, and the nucleotide sequence encoding human CD19 has a GenBank accession number of NM_001178098. In the present invention, CD19 may further include a protein or functional fragments thereof, including mutations, such as point mutations, fragments, insertions, deletions, and splice variants of full-length wild-type CD19.
[0093] In the present invention, the term TNF family member usually refers to a member belonging to the TNF (Tumor Necrosis Factor) family. The TNF family members may include CD40LG (TNFSF5), CD70 (TNFSF7), EDA, FASLG (TNFSF6), LTA (TNFSF1), LTB (TNFSF3), TNFSF4 (OX40L), TNFSF8 (CD153), TNFSF9 (4-1BB), TNFSF10 (TRAIL), TNFSF11 (RANKL), TNFSF12 (TWEAK), TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF17 (BCMA), and TNFSF18. In the present invention, the above TNF family members may also include BCMA and 4-1BB.
[0094] In this invention, the term BCMA usually refers to B cell maturation antigen (BCMA, CD269). BCMA is a member of the tumor necrosis factor receptor (TNF) superfamily capable of binding to B cell activator (BAFF) and proliferation-inducing ligand (APRIL). BCMA is commonly found on the surface of plasma cells in patients with multiple myeloma. Human BCMA has the GenBank accession number BAB60895.1.
[0095] The term CD137 protein, also known as 4-1BB or TNFRS9, is typically a transmembrane protein of the tumor necrosis factor receptor superfamily (TNFRS) and an important modulator of the immune response, specifically a costimulatory molecule whose activation is induced. Previous studies have shown that CD137-mediated monoclonal antibodies exert antitumor effects in many models by increasing costimulatory molecule expression and significantly enhancing the cytolytic T lymphocyte response (see Vinay, Dass S., and Byoung S. Kwon. "4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy." BMB reports 47.3 (2014): 122). Human CD137 has the GenBank accession number NP_001552.2.
[0096] In the present invention, the term HER family member usually refers to a member belonging to the HER (human epidermal growth factor receptor) family. HER family members may include EGFR (ErbB-1), HER2 / c-neu (ErbB-2), Her3 (ErbB-3), and Her4 (ErbB-4). In the present invention, the above HER family members may include HER2.
[0097] In this invention, the term HER2 usually refers to the human HER2 protein belonging to the HER family. See, for example, Semba et al., PNAS(USA)82:6497-6501(1985) and Yamamoto et al., Nature 319:230-234(1986). Human HER2 may have the GenBank accession number XP_024306409.1.
[0098] In this invention, the term GPC family member usually refers to phosphatidylinositol protein glycans (glypicans) that have been identified as six types, designated GPC1 to GPC6, in mammals. Abnormal expression of glypicans occurs in cancers including human hepatocellular carcinoma, ovarian cancer, mesothelioma, pancreatic cancer, glioma, and breast cancer. In this invention, the above GPC family member may include GPC3.
[0099] In this invention, the term GPC3 typically refers to a protein encoded by phosphatidylinositol protein glycan 3 (NCBI database gene ID: 2719), which is an early marker for liver cancer. GPC3 is highly expressed in hepatocellular carcinoma and can be measured in the tissues of patients with early-stage hepatocellular carcinoma. Human GPC3 may have the GenBank accession number AAB87062.1.
[0100] In this invention, the term Mesothelin (or MSLN) usually refers to a tumor differentiation antigen commonly found in mesothelial cells of the pleura, peritoneum, and pericardial lining. It is highly expressed in cancers including malignant mesothelioma, pancreatic cancer, ovarian cancer, and lung adenocarcinoma. Human Mesothelin may have the GenBank accession number AAH09272.1.
[0101] In this invention, the term peripheral blood mononuclear cell usually refers to a cell in the peripheral blood that has a single nucleus (Peripheral blood mononuclear cell, PBMC). The above peripheral blood mononuclear cells may include lymphocytes and mononuclear cells. In this invention, the above peripheral blood mononuclear cells are separated by the difference in specific gravity of each component in the blood using Ficoll-hypaque (glucan-urografin) density gradient centrifugation.
[0102] In the present invention, the term T cell activating factor usually refers to a substance that promotes the activation and proliferation of T cells. In the present invention, the T cell activating factor may include a B lymphocyte surface antigen antibody, a TNF antibody, an intracellular polyester, and / or an antibiotic. In the present invention, the T cell stimulating factor may be selected from the group consisting of CD3 antibody, CD28 antibody, 4-1BB antibody, CD80 antibody, CD86 antibody, PHA, PMA, and ionomycin.
[0103] In the present invention, the term "B lymphocyte surface antigen antibody" usually refers to an antibody that specifically binds to the B lymphocyte surface antigen. In the present invention, the B lymphocyte surface antigen antibody may include CD3 antibody, CD28 antibody, CD80 antibody, and CD86 antibody.
[0104] In the present invention, the term TNF antibody usually refers to an antibody that specifically binds to a member of the TNF family. In the present invention, the above TNF antibody may include a 4-1BB antibody.
[0105] In this invention, the term intracellular polyester typically refers to natural polymer biomaterials that are synthesized by microorganisms and exist as inclusion bodies within cells. Intracellular polyesters possess excellent biological properties. In this invention, intracellular polyesters may contain polyhydroxyalkanoates (PHAs).
[0106] In the present invention, the term "antibiotic" usually refers to an antipathogen or other active metabolite produced by microorganisms or plants and animals that inhibit the developmental function or beneficial effects of other living cells. In the present invention, the above antibiotic may include β-lactams, aminoglycosides, amphenicols, macrolides, polypeptides, nitroimidazoles, and tetracyclines. For example, the above antibiotic may include ionomycin.
[0107] In this invention, the term PHA usually refers to polyhydroxyalkanoates that belong to intracellular polyesters synthesized by various types of bacteria and exist as discontinuous inclusion bodies in the cytoplasm within living organisms. PHA may have physicochemical properties similar to those of synthetic plastics, as well as biodegradability, biocompatibility, optical activity, piezoelectric effect, gas barrier properties, etc.
[0108] In this invention, the term PMA usually refers to phorbol-12-myristate-13-acetate.
[0109] In the present invention, the term "CD3 antibody" usually refers to an antibody or its antigen-binding fragment that specifically binds to CD3. CD3 may be an important differentiation antigen in the T cell membrane that transmits T cell activation signals. The CD3 antibody may be huOKT3g1 or HuM291.
[0110] In this invention, the term CD28 antibody usually refers to an antibody or its antigen-binding fragment that specifically binds to CD28. Human CD28 is located at 2q33 and contains exons and introns similar to CTLA4, which is part of the B7 family and whose ligands both include B7-1 (CD80) and B7-2 (CD86).
[0111] In the present invention, the term cytokine usually refers to small molecule proteins with broad biological activity synthesized and secreted by immune cells (e.g., mononuclear cells, macrophages, T cells, B cells, NK cells, etc.) and certain non-immune cells (e.g., endothelial cells, epidermal cells, fibroblasts, etc.) in response to stimuli. The cytokine may have a wide variety of functions, such as controlling innate and adaptive immunity, hematopoiesis, cell proliferation, APSC pluripotency, and damaged tissue repair. In the present invention, the cytokine may include interleukins, interferons, tumor necrosis factor superfamily, colony-stimulating factors, chemotactic factors, and growth factors. For example, the cytokine may be an interleukin.
[0112] In the present invention, the term interleukin typically refers to a secreted protein or signaling molecule that can promote the development and differentiation of T and / or B lymphocytes and / or hematopoietic cells. Interleukins are synthesized by accessory CD4 T lymphocytes, and mononuclear cells, macrophages, and endothelial cells. In the present invention, the term interleukin may include full-length interleukins or fragments (e.g., truncated forms) or variants thereof that essentially possess the same biological activity as wild-type interleukins (e.g., the same biological activity as wild-type interleukins having at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% of the biological activity). Interleukins used herein may be derived from any mammalian species. In some embodiments, the interleukins are derived from species selected from humans, horses, cattle, mice, pigs, rabbits, cats, dogs, rats, goats, sheep, and non-human primates. In some embodiments, the interleukins are mutants. For example, in the present invention, the cytokine may include one or more selected from the group consisting of IL2, IL21, IL7, and IL15.
[0113] In this invention, the term IL2 usually refers to T cell growth factor, or TCGF. Produced by T cells, IL2 behaves in autocrine and paracrine manner to cause T cell activation, promotion of cytokine production, stimulation of NK cell proliferation, induction of LAK cell production, promotion of B cell proliferation and antibody secretion, and activation of macrophages.
[0114] In the present invention, the term IL21 is homologous to the spatial structures of IL-2, IL-4, and IL-15, and typically promotes the proliferation and differentiation of bone marrow NK cells, and stimulates B cell proliferation in conjunction with anti-CD40 antibodies and T cell proliferation in conjunction with anti-CD3 antibodies.
[0115] In this invention, the term IL-7 typically refers to a glycoprotein secreted by bone marrow stromal cells, the gene of which is located on chromosome 8. IL-7 targeting cells are lymphocytes, in particular, which can promote the proliferation of human and mouse bone marrow-derived B progenitor cells, thymocytes, and peripheral mature T cells. At high concentrations, IL-7 can enhance the cytotoxic activity of macrophages and induce cytokine secretion from mononuclear cells.
[0116] In this invention, the term IL15 typically refers to a substance produced by various cell types, such as active mononuclear macrophages, epidermal cells, and fibroblasts, which shares many similarities with IL2. IL15 belongs to the IL2 family and can regulate the activation and proliferation of T and NK cells, as well as induce B cell proliferation, by altering the expression of Bcl-1 family members (e.g., Bcl-2 and Bcl-XL).
[0117] In the present invention, the term Low-density lipoprotein receptor-related protein (LRP) typically refers to an endogenous protein containing 839 amino acids (after removing 21 amino acid signal peptides). It is embedded in the outer phospholipid layer of LDL (Low-density lipoprotein) particles, belongs to the endocytosis receptor family capable of mediating endocytosis of cholesterol-rich LDL, and is a member of the Low-density lipoprotein receptor (LDLR) gene family. The above-mentioned LRP is most prominently expressed in bronchial epithelial cells, the adrenal gland, and cortical tissue. In the present invention, the above-mentioned Low-density lipoprotein receptor-related protein may include one or more selected from the group of Low-density lipoprotein receptor-related proteins 1 to 12 or their truncated forms.
[0118] In this invention, the terms low-density lipoprotein receptor-associated protein 6 (LRP-6) and low-density lipoprotein receptor-associated protein 5 (LRP-5) usually refer to a single subgroup within the low-density lipoprotein receptor (LDLR) family. Human LRP-6 has the UniProt accession number O75581. Human LRP-5 has the UniProt accession number O75197.
[0119] In this invention, the term "truncated protein" usually refers to a shortened protein. The above-mentioned truncated protein is obtained by removing the N- or C-terminal portion of the protein by protein hydrolysis or structural gene manipulation. Alternatively, the above-mentioned truncated protein advances and terminates translation by generating a stop codon in the structural gene through a nonsense mutation.
[0120] In the present invention, the term "intracellular domain" usually refers to a domain of a protein located in the cell membrane. In the present invention, the intracellular domain can mean the domain of the low-density lipoprotein receptor-associated protein in the cell membrane. In the present invention, the intracellular domain may have amino acid sequences 24 to 243 described in SEQ NO. 24 or sequences having at least 80% homology thereto, or sequences 24 to 231 described in SEQ NO. 28 or sequences having at least 80% homology thereto.
[0121] In the present invention, the term transmembrane region usually refers to a domain in a protein that crosses the cell membrane. In the present invention, the transmembrane region may be a domain in the low-density lipoprotein receptor-related protein that crosses the cell membrane. The transmembrane region is composed of 23 hydrophobic amino acids. The domain provides an anchor function so that LDLR can bind to the cell membrane. In the present invention, the transmembrane region may include the sequence 1 to 23 described in SEQ NO. 24 or an amino acid sequence having at least 80% homology thereto, or the sequence 1 to 23 described in SEQ NO. 28 or an amino acid sequence having at least 80% homology thereto.
[0122] In the present invention, the term LDLR domain usually refers to a domain in the low-density lipoprotein receptor-related protein that is adjacent to an N-segment other than the transmembrane region. This domain has the function of enhancing Wnt signaling. In the present invention, the LDLR domain may have an amino acid sequence at positions 5 to 119 described in SEQ NO. 22 or having at least 80% homology thereto, or an amino acid sequence at positions 4 to 119 described in SEQ NO. 26 or having at least 80% homology thereto.
[0123] In the present invention, the term ribosome hopping site, also referred to as the internal ribosome entry site (IRES), typically refers to a nucleotide sequence of a single segment located in the center of the mRNA sequence and used for translation initiation. The ribosome hopping site enables cap-independent translation initiation. The IRES is typically located at the 5'UTR. In the present invention, the ribosome hopping site may have sequences 1 to 578 as described in SEQ NO. 29.
[0124] In the present invention, the term 2A sequence usually refers to a protease-independent self-cleaving amino acid sequence of a single segment. The 2A sequence contributes to the transcription and synthesis of two types of proteins. In the present invention, the 2A sequence may include sequences 1 to 54 described in SEQ NO. 75.
[0125] In the present invention, the term "pharmaceutically acceptable vector" may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counterions, metal complexes, and / or nonionic surfactants.
[0126] In this invention, the term "retroviral vector" usually refers to an RNA virus that reverse transcribes and synthesizes a DNA complementary strand in infected cells, uses this single-stranded DNA as a template to synthesize a second DNA strand, and incorporates it into the cell's genomic DNA. The retroviral vector self-transcribes and replicates RNA synthesis proteins using enzymes in the host cell, packages the virus, and releases it from the cell to become an infectious virus. The retrovirus has high introduction efficiency and can improve the gene transfection rate.
[0127] In this invention, the term lentiviral vector refers to a gene therapy vector that has been developed based on HIV-1 (human immunodeficiency virus type I). Both lentiviral vectors have the ability to infect both dividing and non-dividing cells. They can effectively infect almost all mammalian cells, including neuronal cells and hepatocytes, and have high infection efficiency. Lentiviruses achieve sustained expression by incorporating foreign genes into the host's chromosomes.
[0128] In this invention, the term transposon plasmid typically refers to an autonomously replicating and transposing basic unit found in chromosomal DNA. The transposon plasmid "jumps" from one location to another in the genome through a series of processes including cleavage and reintegration.
[0129] In this invention, the term "tumor" usually refers to a neogrowth produced when certain cells in a local tissue in a living organism lose normal control of their proliferation at the genetic level under the influence of various oncogenic factors, resulting in clonal abnormal proliferation. Such neogrowths are also called neoplasms because they often occupy a large amount of space. In this invention, the above-mentioned tumor may include solid tumors and non-solid tumors. In this invention, the above-mentioned tumor may include liver cancer, lung cancer, leukemia, and mesothelioma.
[0130] In this invention, the term "significant increase" typically refers to an increase in a level (e.g., protein expression level, cell number), such as P<0.05, P<0.04, P<0.03, P<0.02, P<0.01, P<0.005, or P<0.001. Furthermore, for example, the above "significant increase" means an increase of 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100% or more.
[0131] In the present invention, the term "no increase" generally means that the level (e.g., protein expression level, cell number) is the same as before, or increases by 3% or less, 2% or less, 1% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, or 0.1% or less.
[0132] In the present invention, the term "about" usually means that a given value varies within a range of 0.5%-10% or more or less than or equal to 0.5%-10% of the given value, for example, within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% or more or less than or equal to 10% of the given value.
[0133] Low-density lipoprotein receptor-related proteins or their fragments In the present invention, the low-density lipoprotein receptor-related protein may include one or more selected from the group of low-density lipoprotein receptor-related proteins 1 to 12 and their functional fragments.
[0134] In the present invention, the low-density lipoprotein receptor-related protein or its fragment may be of mammalian origin. For example, it may be derived from humans, macaques, rats, and mice.
[0135] In the present invention, the functional fragment may include a fragment or a truncated form of the low-density lipoprotein receptor-related protein having the low-density lipoprotein receptor-related protein activity. For example, the low-density lipoprotein receptor-related protein may include low-density lipoprotein receptor-related protein 6 and its truncated form, and / or low-density lipoprotein receptor-related protein 5 and its truncated form.
[0136] In the present invention, the truncated form of the low-density lipoprotein receptor-related protein 6 may include the intracellular domain of the low-density lipoprotein receptor-related protein 6, and / or the truncated form of the low-density lipoprotein receptor-related protein 5 may include the intracellular domain of the low-density lipoprotein receptor-related protein 5. Also, for example, the truncated form of the low-density lipoprotein receptor-related protein 6 may include the transmembrane domain of the low-density lipoprotein receptor-related protein 6 and the LDLR domain of the low-density lipoprotein receptor-related protein 6, and / or the truncated form of the low-density lipoprotein receptor-related protein 5 may include the transmembrane domain of the low-density lipoprotein receptor-related protein 5 and the LDLR domain of the low-density lipoprotein receptor-related protein 5.
[0137] In the present invention, the low-density lipoprotein receptor-related protein or fragment thereof contains an amino acid sequence represented by any of SEQ ID NO: 22, 24, 26, and 28, or an amino acid sequence having at least 80% homology thereto.
[0138] In the present invention, the nucleic acid molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof contains a nucleic acid sequence represented by any of SEQ ID NO: 21, 23, 25, and 27, or a nucleic acid sequence having at least 80% homology thereto.
[0139] Genetically modified immune cells The present invention provides genetically modified immune cells that increase the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the above-mentioned immune cells.
[0140] In the present invention, the genetically modified immune cells may include lymphocytes. In the present invention, the genetically modified immune cells include genetically modified T cells. In the present invention, the genetically modified immune cells include genetically modified memory stem cell-like T cells (TSCMs) and / or genetically modified central memory T cells (TCMs). In the present invention, the TSCMs are CCR7 + and / or CD62L + It contains. In the present invention, the above TSCM is further CD45RA + Or CD45RA - CD45RO + Or CD45RO - CD27 + CD28 + CD127 + CD122 + CD3 + CD4 + and CD8 + It includes one or more characteristics selected from the group.
[0141] In the present invention, the immune cells may include genetically modified immune cells, and the genetically modified immune cells express chimeric antigen receptors (CARs).
[0142] In the present invention, the CAR may include an intracellular domain, and the intracellular domain may include a signaling domain and / or a co-stimulatory domain.
[0143] For example, the above signal transduction domain may include a portion selected from the group consisting of CD3ζ signal transduction domains, CD3δ signal transduction domains, and CD3ε signal transduction domains. For example, the above signal transduction domain may contain an amino acid sequence represented by SEQ ID NO: 18 or an amino acid sequence having at least 80% homology thereto, and the nucleic acid molecule encoding the above signal transduction domain may contain a nucleic acid sequence represented by SEQ ID NO: 17 or a nucleic acid sequence having at least 80% homology thereto.
[0144] For example, the above-mentioned co-stimulatory domain may include a portion selected from the group consisting of the CD27 co-stimulatory domain, the CD28 co-stimulatory domain, and the 4-1BB co-stimulatory domain. For example, the above-mentioned co-stimulatory domain may contain an amino acid sequence represented by either SEQ ID NO:14 or SEQ ID NO:16, or an amino acid sequence having at least 80% homology thereto, and the nucleic acid molecule encoding the above-mentioned co-stimulatory domain may contain a nucleic acid sequence represented by either SEQ ID NO:13 or SEQ ID NO:15, or a nucleic acid sequence having at least 80% homology thereto.
[0145] In the present invention, the CAR may include a hinge region. For example, the hinge region may include a portion selected from the group consisting of the hinge region of IgG4, the hinge region of IgG1, and the hinge region of CD8. For example, the hinge region may contain an amino acid sequence represented by SEQ ID NO: 31 or an amino acid sequence having at least 80% homology thereto, and the nucleic acid molecule encoding the hinge region may contain a nucleic acid sequence represented by SEQ ID NO: 32 or a nucleic acid sequence having at least 80% homology thereto.
[0146] In the present invention, the CAR may include a transmembrane region. For example, the transmembrane region may include a portion selected from the group consisting of the CD8 transmembrane region, the CD28 transmembrane region, and the CD24 transmembrane region. For example, the transmembrane region may contain an amino acid sequence represented by SEQ ID NO: 33 or an amino acid sequence having at least 80% homology thereto, and the nucleic acid molecule encoding the transmembrane region may contain a nucleic acid sequence represented by SEQ ID NO: 34 or a nucleic acid sequence having at least 80% homology thereto.
[0147] In the present invention, the CAR may include a target-directing portion. In the present invention, the target-directing portion may include an antibody or antigen-binding fragment. The antigen-binding fragment may be selected from the group consisting of Fab, Fab', F(ab)2, F(ab')2, Fv, and ScFv fragments. For example, the target-directing portion may be ScFv.
[0148] In the present invention, the target-directed portion can specifically bind to and / or recognize tumor antigens. For example, the target-directed portion can specifically bind to and / or recognize targets selected from the group consisting of B lymphocyte surface antigens, TNF family members, HER family members, and GPC family members. Alternatively, for example, the target-directed portion can specifically bind to and / or recognize targets selected from the group consisting of CD19, BCMA, HER2, Mesothelin, and GPC3.
[0149] In the present invention, the target-directed portion may be an antibody or its antigen-binding fragment that specifically binds to and / or recognizes CD19. The antibody or its antigen-binding fragment may include a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 46 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 47 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 48 or an amino acid sequence having at least 80% homology thereto. The light chain variable region may contain an amino acid sequence represented by SEQ ID NO: 50 or an amino acid sequence having at least 80% homology thereto. In the present invention, the antibody or its antigen-binding fragment may include a heavy chain variable region comprising HCDR1 containing an amino acid sequence represented by SEQ ID NO: 43 or an amino acid sequence having at least 80% homology thereto, HCDR2 containing an amino acid sequence represented by SEQ ID NO: 44 or an amino acid sequence having at least 80% homology thereto, and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 45 or an amino acid sequence having at least 80% homology thereto. The heavy chain variable region may contain an amino acid sequence represented by SEQ ID NO: 49 or an amino acid sequence having at least 80% homology thereto.
[0150] In the present invention, the target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes BCMA, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 54 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 55 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 56 or an amino acid sequence having at least 80% homology thereto. The light chain variable region may contain an amino acid sequence represented by SEQ ID NO: 58 or an amino acid sequence having at least 80% homology thereto. In the present invention, the antibody or its antigen-binding fragment may include a heavy chain variable region comprising HCDR1 containing an amino acid sequence represented by SEQ ID NO: 51 or an amino acid sequence having at least 80% homology thereto, HCDR2 containing an amino acid sequence represented by SEQ ID NO: 52 or an amino acid sequence having at least 80% homology thereto, and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 53 or an amino acid sequence having at least 80% homology thereto. The heavy chain variable region may contain an amino acid sequence represented by SEQ ID NO: 57 or an amino acid sequence having at least 80% homology thereto.
[0151] In the present invention, the target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes HER2, comprising a light chain variable region consisting of LCDR1 containing an amino acid sequence represented by SEQ ID NO: 70 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 71 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 72 or an amino acid sequence having at least 80% homology thereto. The light chain variable region may contain an amino acid sequence represented by SEQ ID NO: 74 or an amino acid sequence having at least 80% homology thereto. In the present invention, the antibody or its antigen-binding fragment may include a heavy chain variable region comprising HCDR1 containing an amino acid sequence represented by SEQ ID NO: 67 or an amino acid sequence having at least 80% homology thereto, HCDR2 containing an amino acid sequence represented by SEQ ID NO: 68 or an amino acid sequence having at least 80% homology thereto, and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 69 or an amino acid sequence having at least 80% homology thereto. The heavy chain variable region may contain an amino acid sequence represented by SEQ ID NO: 73 or an amino acid sequence having at least 80% homology thereto.
[0152] In the present invention, the target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes mesothelin, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 62 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 63 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 64 or an amino acid sequence having at least 80% homology thereto. The light chain variable region may contain an amino acid sequence represented by SEQ ID NO: 66 or an amino acid sequence having at least 80% homology thereto. The antibody or its antigen-binding fragment may include a heavy chain variable region comprising HCDR1 containing the amino acid sequence represented by SEQ ID NO: 59 or an amino acid sequence having at least 80% homology thereto, HCDR2 containing the amino acid sequence represented by SEQ ID NO: 60 or an amino acid sequence having at least 80% homology thereto, and HCDR3 containing the amino acid sequence represented by SEQ ID NO: 61 or an amino acid sequence having at least 80% homology thereto. The heavy chain variable region may contain the amino acid sequence represented by SEQ ID NO: 65 or an amino acid sequence having at least 80% homology thereto.
[0153] In the present invention, the target-directed portion is an antibody or antigen-binding fragment that specifically binds to and / or recognizes GPC3, comprising a light chain variable region comprising LCDR1 containing an amino acid sequence represented by SEQ ID NO: 38 or an amino acid sequence having at least 80% homology thereto, LCDR2 containing an amino acid sequence represented by SEQ ID NO: 39 or an amino acid sequence having at least 80% homology thereto, and LCDR3 containing an amino acid sequence represented by SEQ ID NO: 40 or an amino acid sequence having at least 80% homology thereto. The light chain variable region may contain an amino acid sequence represented by SEQ ID NO: 42 or an amino acid sequence having at least 80% homology thereto. In the present invention, the antibody or its antigen-binding fragment may include a heavy chain variable region comprising HCDR1 containing an amino acid sequence represented by SEQ ID NO: 35 or an amino acid sequence having at least 80% homology thereto, HCDR2 containing an amino acid sequence represented by SEQ ID NO: 36 or an amino acid sequence having at least 80% homology thereto, and HCDR3 containing an amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having at least 80% homology thereto. The heavy chain variable region may contain an amino acid sequence represented by SEQ ID NO: 41 or an amino acid sequence having at least 80% homology thereto.
[0154] In the present invention, the target-directed portion may contain an amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, and 10, or an amino acid sequence having at least 80% homology thereto. In the present invention, the nucleic acid molecule encoding the target-directed portion may contain a nucleic acid sequence represented by SEQ ID NO: 1, 3, 5, 7, and 9, or a nucleic acid sequence having at least 80% homology thereto.
[0155] In this invention, the enthalpy of the amino acid position of the CDR is calculated according to Kabat.
[0156] It should also be understood that the proteins, polypeptides, amino acid sequences, and / or nucleic acid sequences according to the present invention include, at a minimum, variants or homologs having the same or similar function as the above-mentioned protein or polypeptide, and / or nucleic acid sequences encoding variants or homologs having the same or similar function as the above-mentioned protein or polypeptide.
[0157] In the present invention, the variant may be a protein or polypeptide in which one or more amino acids are substituted, deleted, or added to the amino acid sequence of the protein and / or polypeptide (e.g., an antibody or fragment thereof that specifically binds to the GPC3 protein, or the low-density lipoprotein receptor-related protein or fragment thereof). For example, the functional variant may already contain a protein or polypeptide that has undergone an amino acid change by substitution, deletion, and / or insertion of at least one, for example, 1 to 30, 1 to 20, or 1 to 10, or for example, 1, 2, 3, 4, or 5 amino acids. The functional variant can essentially retain the biological properties of the protein or polypeptide before the change (e.g., substitution, deletion, or addition). For example, the functional variant can retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (e.g., antigen-binding ability, or the biological function of the low-density lipoprotein receptor-related protein or fragment thereof) of the protein or polypeptide before the change. For example, the substitution may be a conservative substitution.
[0158] In the present invention, the homologue may be a protein or polypeptide having at least about 85% (for example, at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more) sequence homology to the amino acid sequence of the protein and / or polypeptide (for example, an antibody or fragment thereof that specifically binds to the GPC3 protein, or the low-density lipoprotein receptor-related protein or fragment thereof).
[0159] In this invention, homology typically refers to the identity, similarity, or correlation between two or more sequences. The "sequence homology percentage" is obtained by comparing two sequences to be aligned across a comparison window, counting the number of positions in the two sequences where the same nucleic acid base (e.g., A, T, C, G, I) or the same amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) exist, calculating the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window (i.e., the size of the window), and multiplying the result by 100 to obtain the sequence homology percentage. Alignment for determining the sequence homology percentage is carried out according to various well-known means in the art, such as publicly available computer software, such as BLAST, BLAST-2, ALIGN, and Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for sequence alignment, including the full-length sequence range being compared and any algorithm necessary to achieve maximum alignment in the target sequence region. The homology can also be measured using the FASTA and BLAST algorithms. The FASTA algorithm is described in "An Improved Tool for Biological Sequence Comparison" by WRPearson and DJLipman, Proceedings of the National Academy of Sciences (Proc. Natl. Acad. Sci.), 85:2444-2448, 1988, and "A Fast and Sensitive Search for Protein Identity" by DJLipman and WRPearson, Science, 227:1435-1441, 1989. The BLAST algorithm is described in "A Basic Local Alignment Search Tool" by S. Altschul, W. Gish, W. Miller, EWMyers and D. Lipman, Journal of Molecular Biology, 215:403-410, 1990.
[0160] In the present invention, the CAR may sequentially contain the target-directing portion, the hinge region, the transmembrane region, the co-stimulatory domain, and the signal transduction domain from the N end to the C end.
[0161] In the present invention, the polynucleotide molecule encoding the CAR may sequentially contain, from the 5' end to the 3' end, a nucleotide sequence encoding the target-directing region, a nucleotide sequence encoding the hinge region, a nucleotide sequence encoding the transmembrane region, a nucleotide sequence encoding the transmembrane region, a nucleotide sequence encoding the co-stimulatory domain, and a nucleotide sequence encoding the signal transduction domain.
[0162] In the present invention, the polynucleotide molecule encoding the CAR may further contain a leader sequence. For example, the nucleic acid molecule encoding the leader sequence may contain a nucleic acid sequence represented by SEQ ID NO: 30 or a nucleic acid sequence having at least 80% homology thereto. The nucleic acid molecule encoding the leader sequence may be located at the 5' end of the nucleotide sequence encoding the target-directing portion.
[0163] In the present invention, the genetically modified immune cells can express the low-density lipoprotein receptor-related protein or a fragment thereof. For example, the genetically modified immune cells may have a vector capable of expressing the low-density lipoprotein receptor-related protein or a fragment thereof. The vector may contain a nucleotide molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof. For example, the polynucleotide molecule may contain a nucleic acid sequence represented by any of SEQ ID NO: 21, 23, 25, and 27, or a nucleic acid sequence having at least 80% homology thereto. Alternatively, for example, the vector may be selected from retroviral vectors, lentiviral vectors, and / or transposon plasmids.
[0164] In the present invention, the genetically modified immune cells can express the chimeric antigen receptor (CAR). For example, the genetically modified immune cells may include a vector capable of expressing the chimeric antigen receptor (CAR). The vector may include a creotide molecule encoding the chimeric antigen receptor (CAR). Alternatively, the vector may be selected from the group consisting of retroviral vectors, lentiviral vectors, and / or transposon plasmids.
[0165] In the present invention, the vector capable of expressing the low-density lipoprotein receptor-related protein or a fragment thereof and the vector capable of expressing the chimeric antigen receptor (CAR) may be the same vector or different vectors, and one or more of these vectors may express the low-density lipoprotein receptor-related protein or a fragment thereof and the chimeric antigen receptor (CAR), and the genetically modified immune cells may possess both the low-density lipoprotein receptor-related protein or a fragment thereof and the chimeric antigen receptor (CAR).
[0166] For example, the vector capable of expressing the low-density lipoprotein receptor-related protein or a fragment thereof and the vector capable of expressing the chimeric antigen receptor (CAR) may be the same vector. In the vector, the nucleotide molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof and the nucleotide molecule encoding the chimeric antigen receptor (CAR) may be located on the same expression cassette. For example, the nucleotide molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof may be located at the 3' end of the nucleotide molecule encoding the chimeric antigen receptor (CAR).
[0167] In the present invention, the nucleotide molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof may be directly or indirectly linked to the nucleotide molecule encoding the chimeric antigen receptor (CAR). For example, the indirect linkage described above may be performed by linking sequences. The 5' end of the linked sequence may be linked to the 3' end of the nucleotide molecule encoding the low-density lipoprotein receptor-related protein or a fragment thereof, and the 3' end of the linked sequence may be linked to the 5' end of the nucleotide molecule encoding the chimeric antigen receptor (CAR). In the present invention, the linked sequence may contain a nucleic acid sequence represented by SEQ ID NO: 19 and 29 or a nucleic acid sequence having at least 80% homology thereto.
[0168] In the present invention, the low-density lipoprotein receptor-related protein or its fragment obtained by expression of the genetically modified immune cells and the chimeric antigen receptor (CAR) may be two independent proteins. That is, these two may form any form of di(polymer) or protein complex without any linkage whatsoever. However, the low-density lipoprotein receptor-related protein or its fragment obtained by expression of the genetically modified immune cells and the chimeric antigen receptor (CAR) may be linked to each other. For example, the low-density lipoprotein receptor-related protein or its fragment and the chimeric antigen receptor may form a complex because the proteins formed by the translation of these two types of proteins cannot be completely cleaved.
[0169] Preparation method The present invention provides a method for preparing the above-mentioned genetically modified immune cells, comprising the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the above-mentioned genetically modified immune cells.
[0170] The present invention further provides a method for preparing the above composition, comprising the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the above-mentioned genetically modified immune cells.
[0171] In the present invention, the above method further includes peripheral blood mononuclear cells (PBMCs) and CD3 + T lymphocytes, CD8 + T lymphocytes, CD4 + The procedure may include a step of obtaining T lymphocytes or regulatory T cells by isolating them.
[0172] In the present invention, the above method may include the step of activating the genetically modified immune cells, which consists of isolating them and administering T cell culture medium to the isolated genetically modified immune cells.
[0173] In the present invention, the T cell medium may be selected from one or more types of the group consisting of DMEM medium, 1640 medium, MEM medium, and X-VIVO medium.
[0174] In the present invention, the above method may further include the step of adding one or more T cell stimulating factors to the isolated peripheral blood mononuclear cells (PBMCs).
[0175] For example, the T cell stimulating factor may be selected from the group consisting of B lymphocyte surface antigen antibodies, TNF antibodies, intracellular polyesters, and antibiotics. Alternatively, for example, the T cell stimulating factor may be selected from the group consisting of CD3 antibodies, CD28 antibodies, 4-1BB antibodies, CD80 antibodies, CD86 antibodies, PHA, PMA, and ionomycin.
[0176] In the present invention, the T cell stimulating factor may include a CD3 antibody with a concentration of 1 to 10,000 ng / mL. For example, the CD3 antibody may have a concentration of 1 to 9,000 ng / mL, 1 to 5,000 ng / mL, 1 to 4,000 ng / mL, 1 to 3,000 ng / mL, 1 to 1,000 ng / mL, 1 to 500 ng / mL, 1 to 400 ng / mL, 1 to 300 ng / mL, 1 to 200 ng / mL, 1 to 100 ng / mL, 1 to 50 ng / mL, 1 to 40 ng / mL, 1 to 30 ng / mL, 1 to 20 ng / mL, 1 to 10 ng / mL, or 1 to 5 ng / mL. In the present invention, the T cell stimulating factor may include a CD28 antibody with a concentration of 1 to 10,000 ng / mL. For example, the above CD28 antibody may have concentrations of 1-9000 ng / mL, 1-5000 ng / mL, 1-4000 ng / mL, 1-3000 ng / mL, 1-1000 ng / mL, 1-500 ng / mL, 1-400 ng / mL, 1-300 ng / mL, 1-200 ng / mL, 1-100 ng / mL, 1-50 ng / mL, 1-40 ng / mL, 1-30 ng / mL, 1-20 ng / mL, 1-10 ng / mL, or 1-5 ng / mL.
[0177] In the present invention, the above method may further include adding one or more cytokine agents to the isolated PBMCs. In the present invention, the cytokine agents may include interleukins. For example, the interleukins may include one or more selected from the group consisting of IL2, IL21, IL7, and IL15.
[0178] In the present invention, the above interleukin may contain IL2 having a concentration of 0.1 to 10000 U / mL. For example, the above IL2 may have concentrations of 0.1 to 8000 U / mL, 0.1 to 6000 U / mL, 0.1 to 4000 U / mL, 0.1 to 2000 U / mL, 5 to 2000 U / mL, 5 to 1900 U / mL, 5 to 1800 U / mL, 5 to 1700 U / mL, 5 to 1600 U / mL, 5 to 1500 U / mL, 5 to 1400 U / mL, 5 to 1300 U / mL, 5 to 1200 U / mL, 5 to 1100 U / mL, and 5 to 1000 U / mL. The concentration may be L, 5-900 U / mL, 5-800 U / mL, 5-700 U / mL, 5-600 U / mL, 5-500 U / mL, 5-400 U / mL, 5-300 U / mL, 5-200 U / mL, 5-500 U / mL, 5-400 U / mL, 5-300 U / mL, 5-200 U / mL, 5-100 U / mL, 5-50 U / mL, 5-40 U / mL, 5-30 U / mL, 5-20 U / mL, or 5-10 U / mL.
[0179] In the present invention, the interleukin may contain IL21, which may have a concentration of 0.01 to 1000 ng / mL. For example, the concentration of IL21 may be 0.01 to 800 ng / mL, 0.01 to 600 ng / mL, 0.01 to 400 ng / mL, 0.01 to 200 ng / mL, 0.01 to 100 ng / mL, 0.1 to 100 ng / mL, 0.1 to 90 ng / mL, 0.1 to 80 ng / mL, 0.1 to 70 ng / mL, 0.1 to 60 ng / mL, 0.1 to 50 ng / mL, 0.1 to 40 ng / mL, 0.1 to 30 ng / mL, 0.1 to 20 ng / mL, 0.1 to 10 ng / mL, or 0.1 to 5 ng / mL.
[0180] In the present invention, the above-mentioned interleukin may contain IL7, which may have a concentration of 0.01 to 1000 ng / mL. For example, the above-mentioned IL7 may have a concentration of 0.01 to 800 ng / mL, 0.01 to 600 ng / mL, 0.01 to 400 ng / mL, 0.01 to 200 ng / mL, 0.01 to 100 ng / mL, 0.1 to 100 ng / mL, 0.1 to 90 ng / mL, 0.1 to 80 ng / mL, 0.1 to 70 ng / mL, 0.1 to 60 ng / mL, 0.1 to 50 ng / mL, 0.1 to 40 ng / mL, 0.1 to 30 ng / mL, 0.1 to 20 ng / mL, 0.1 to 10 ng / mL, or 0.1 to 5 ng / mL.
[0181] In the present invention, the interleukin may contain IL15, which may have a concentration of 0.01 to 1000 ng / mL. For example, the concentration of IL15 may be 0.01 to 800 ng / mL, 0.01 to 600 ng / mL, 0.01 to 400 ng / mL, 0.01 to 200 ng / mL, 0.01 to 100 ng / mL, 0.1 to 100 ng / mL, 0.1 to 90 ng / mL, 0.1 to 80 ng / mL, 0.1 to 70 ng / mL, 0.1 to 60 ng / mL, 0.1 to 50 ng / mL, 0.1 to 40 ng / mL, 0.1 to 30 ng / mL, 0.1 to 20 ng / mL, 0.1 to 10 ng / mL, or 0.1 to 5 ng / mL.
[0182] Promotes immune cell proliferation, enhances memory immune cell production, suppresses immune cell differentiation, enhances cytokine release, and increases tumor killing ability. On the other hand, the present invention provides a method for promoting immune cell proliferation, comprising the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells.
[0183] On the other hand, the present invention provides a method for promoting memory immune cell production, comprising the step of promoting the differentiation of the immune cells into memory immune cells by increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the immune cells.
[0184] On the other hand, the present invention provides a method for suppressing immune cell differentiation, which includes the step of suppressing the differentiation of the immune cells into differentiated immune cells by increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the immune cells.
[0185] On the other hand, the present invention provides a method for enhancing cytokine release by immune cells, comprising the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the immune cells.
[0186] In the present invention, the cytokine may contain interleukin, interferon and / or tumor necrosis factor. In the present invention, the cytokine may contain IL-2, IL4, IL6, IL7, IL10, IL21, TNF-α and / or IFNγ.
[0187] On the other hand, the present invention provides a method for increasing the tumor-killing ability of immune cells, comprising the step of increasing the expression level of low-density lipoprotein receptor-related proteins or fragments thereof in the immune cells.
[0188] On the other hand, the present invention provides a method for preventing tumor recurrence in a subject susceptible to tumors, comprising the step of administering immune cells in which the expression level of low-density lipoprotein receptor-related protein or a fragment thereof is enhanced to the subject.
[0189] On the other hand, the present invention provides a method for treating tumors in subjects in need, comprising the step of administering to the subject immune cells in which the expression levels of low-density lipoprotein receptor-related proteins or fragments thereof are enhanced.
[0190] In the present invention, the tumor may be selected from liver cancer, lung cancer, leukemia, and mesothelioma. In the present invention, the method may include an in vivo method and an in vitro method.
[0191] In the present invention, increasing the expression level as described above means significantly increasing the expression level of the low-density lipoprotein receptor-related protein or its fragments in the immune cells compared to the expression level of control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the control immune cells are the corresponding immune cells in which the expression level of the low-density lipoprotein receptor-related protein or its fragments is not basically increased.
[0192] In the present invention, promoting the production of memory immune cells means significantly increasing the number of memory immune cells produced by the above-mentioned immune cells compared to the number of memory immune cells produced by control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the above-mentioned control immune cells are corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not fundamentally increased.
[0193] In the present invention, suppressing the aforementioned immune cell differentiation means reducing the number of differentiated immune cells produced by the above-mentioned immune cells to a significantly greater extent than the number of memory immune cells produced by the control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the above-mentioned control immune cells are corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not basically elevated.
[0194] In the present invention, enhancing cytokine release by immune cells means significantly increasing the number of cytokines released by the immune cells compared to the number of cytokines released by control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the control immune cells are the corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not fundamentally increased.
[0195] In the present invention, increasing the tumor-killing ability of the aforementioned immune cells means significantly improving the tumor-killing ability of the immune cells compared to the tumor-killing ability of control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the control immune cells are corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not fundamentally increased.
[0196] In the present invention, preventing tumor recurrence in the aforementioned subject means significantly increasing the ability of the immune cells to prevent tumor recurrence in the subject compared to the ability of the control immune cells to prevent tumor recurrence in the subject (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the control immune cells are corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not fundamentally increased.
[0197] In the present invention, treating a tumor in a subject in need as described above means significantly increasing the therapeutic effect of the immune cells on the tumor compared to the therapeutic effect of control immune cells (for example, by 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more), provided that the control immune cells are corresponding immune cells in which the expression level of low-density lipoprotein receptor-related protein or its fragments is not fundamentally increased.
[0198] For example, the corresponding immune cells described above may include lymphocytes. In the present invention, the corresponding immune cells described above may include T cells. In the present invention, the T cells described above may include memory stem cell-like T cells (TSCMs) and / or central memory T cells (TCMs). In the present invention, the TSCMs described above are CCR7 + and / or CD62L + It may be so. In the present invention, the above TSCM is further CD45RA + Or CD45RA - CD45RO + Or CD45RO - CD27 + CD28 + CD127 + CD122 + CD3 + CD4 + and CD8 + The immune cells may have one or more characteristics selected from the group. In the present invention, the corresponding immune cells may include genetically modified immune cells that express chimeric antigen receptors (CARs). In the present invention, the corresponding immune cells may include genetically modified T cells.
[0199] In the present invention, the content of the low-density lipoprotein receptor-related protein or its fragment in the corresponding immune cells is either only equal to the expression level of the low-density lipoprotein receptor-related protein or its fragment in a normal individual, or is not fundamentally higher than the content of the low-density lipoprotein receptor-related protein or its fragment in a normal individual. For example, "not fundamentally higher" means at most 4.5%, at most 4%, at most 3%, at most 2%, at most 1%, at most 0.5%, at most 0.3%, at most 0.1%, at most 0.01%, or less. In the present invention, the corresponding immune cells do not need to contain a vector having a nucleotide molecule encoding the low-density lipoprotein receptor-related protein or its fragment, and / or the corresponding immune cells do not need to contain a nucleotide molecule encoding the low-density lipoprotein receptor-related protein or its fragment.
[0200] In the present invention, the method for measuring the expression levels of the low-density lipoprotein receptor-related protein or its fragments, and / or the cytokines, may include quantitative PCR, Western blot, and immunohistochemistry.
[0201] In the present invention, the method for measuring the memory immune cells and / or differentiated immune cells may include flow cytometry, immunofluorescence antibody method, electromagnetic bead separation method, ELISA, ELISPOT, and quantitative PCR.
[0202] In the present invention, the efficacy of tumor treatment can be evaluated using an index selected from the group consisting of tumor volume, overall survival (OS), complete remission (DOR), disease stability period, disease-free survival (DFS), progression-free survival (PFS), disease control rate (DCR), objective response rate (ORR), and / or clinical usefulness.
[0203] In the present invention, to evaluate the preventive effect against tumor recurrence in subjects, an indicator selected from the group of tumor markers (e.g., tumor-associated antigens, tumor-specific genes, and tumor suppressor genes), histological detection results (e.g., epithelial hyperplasia, degree of polyp disappearance), imaging findings (e.g., mammography test results), and / or serum markers (e.g., serum free DNA, methylated DNA) expression levels can be used.
[0204] Composition and its uses The present invention provides a composition comprising the above-mentioned genetically modified immune cells.
[0205] In the present invention, the above composition may further optionally contain a pharmaceutically acceptable vector. The pharmaceutically acceptable vector may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counterions, metal complexes and / or nonionic surfactants.
[0206] In the present invention, the above composition can be prepared for oral administration, intravenous administration, intramuscular administration, in situ administration at the tumor site, inhalation, rectal administration, vaginal administration, transdermal administration, or administration by subcutaneous storage.
[0207] The above-mentioned pharmaceutical composition is used to suppress tumor growth. For example, the pharmaceutical composition of the present invention can suppress or delay the development or progression of a disease, reduce the size of a tumor (and thus essentially eliminate the tumor), and / or reduce and / or stabilize the disease state.
[0208] The composition according to the present invention may contain a therapeutically effective amount of the above antibody or its antigen-binding fragment. The therapeutically effective amount is a dose for preventing and / or treating (at least partially treating) a disease (e.g., cancer) and / or any of its complications in a subject at risk of progression.
[0209] The present invention provides uses for the genetically modified cells and / or compositions in the preparation of pharmaceuticals for treating and / or preventing tumors.
[0210] In the present invention, the tumor may be selected from liver cancer, lung cancer, leukemia, and mesothelioma.
[0211] The following examples are intended solely to illustrate the requirements, methods, and operational modes of the present invention, without relying on any theory, and do not limit the scope of the present invention.
[0212] Examples Example 1: Construction of a lentiviral vector The above CAR-T proteins were artificially synthesized by synthesizing fragments containing CAR structures, using targeted GPC3, CD19, Mesothelin (MSLN), HER2, and BCMA as examples, and then used to create lentiviral vectors (LV100A, System The following lentiviruses were obtained by constructing a biosciences company and then transfecting them (as shown in Figure 1) in accordance with the description of this specification: GPC3-41BB, GPC3-41BB-L6, GPC3-41BB-TL6, GPC3-CD28, GPC3-CD28-L6, GPC3-CD28-TL6, GPC3-41BB-L5, GPC3-41BB-TL5, BCMA-41BB, BCMA-41BB-L6, BCMA-41BB-TL6, CD19-41BB, CD19-41BB-L6, CD19-41BB-TL6, MSLN-41BB, MSLN-41BB-L6, MSLN-41BB-TL6, HER2-41BB, HER2-41BB-L6, and HER2-41BB-TL6.
[0213] GPC3-41BB is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, 41BB, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.15, and SEQ ID NO.17, respectively.
[0214] GPC3-41BB-L6 is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0215] GPC3-41BB-TL6 is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0216] GPC3-41BB-L5 is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L5 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.25, respectively.
[0217] GPC3-41BB-TL5 is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL5 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.27, respectively.
[0218] GPC3-CD28 was constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, CD28, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.13, and SEQ ID NO.17, respectively.
[0219] GPC3-CD28-L6 is constructed by sequentially splicing the leader sequence, GPC3 ScFv, CD8 hinge region and transmembrane region, CD28, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0220] GPC3-CD28-TL6 is constructed by sequentially splicing the leader sequence, GPC3ScFv, CD8 hinge region and transmembrane region, CD28, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.1, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0221] BCMA-41BB is constructed by sequentially splicing the leader sequence, BCMAScFv, CD8 hinge region and transmembrane region, 41BB, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.5, SEQ ID NO.11, SEQ ID NO.15, and SEQ ID NO.17, respectively.
[0222] BCMA-41BB-L6 is constructed by sequentially splicing the leader sequence, BCMAScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.5, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0223] BCMA-41BB-TL6 is constructed by sequentially splicing the leader sequence, BCMAScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.5, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0224] CD19-41BB is constructed by sequentially splicing the leader sequence, CD19ScFv, CD8 hinge region and transmembrane region, 41BB, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.3, SEQ ID NO.11, SEQ ID NO.15, and SEQ ID NO.17, respectively.
[0225] CD19-41BB-L6 is constructed by sequentially splicing the leader sequence, CD19ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.3, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0226] CD19-41BB-TL6 is constructed by sequentially splicing the leader sequence, CD19ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.3, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0227] MSLN-41BB is constructed by sequentially splicing the leader sequence, MSLNScFv, CD8 hinge region and transmembrane region, 41BB, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.7, SEQ ID NO.11, SEQ ID NO.15, and SEQ ID NO.17, respectively.
[0228] MSLN-41BB-L6 is constructed by sequentially splicing the leader sequence, MSLNScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.7, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0229] MSLN-41BB-TL6 is constructed by sequentially splicing the leader sequence, MSLNScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.7, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0230] HER2-41BB is constructed by sequentially splicing the leader sequence, HER2ScFv, CD8 hinge region and transmembrane region, 41BB, and CD3zeta from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.15, and SEQ ID NO.17, respectively.
[0231] HER2-41BB-L6 is constructed by sequentially splicing the leader sequence, HER2ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and L6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.21, respectively.
[0232] HER2-41BB-TL6 is constructed by sequentially splicing the leader sequence, HER2 ScFv, CD8 hinge region and transmembrane region, 41BB, CD3zeta, 2A, and TL6 from the 5' end to the 3' end. Its nucleotide sequences are shown in SEQ ID NO.30, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, and SEQ ID NO.23, respectively.
[0233] Example 2: Lentiviral-infected T cells Using ficoll isolate, 1 × 10⁶ units were extracted from fresh human peripheral blood. 7 Larger peripheral blood mononuclear lymphocytes (PBMCs) were isolated and collected. Anti-human CD3 and anti-human CD28 antibodies were diluted in PBS to a final concentration of 1 μg / ml. The diluted antibody mixture was then added to a cell culture dish, spread evenly, and incubated at room temperature for 2 hours. After 2 hours, the antibody mixture was washed once with PBS. The isolated PBMCs were then collected to a final concentration of 1 × 10⁶. 6 T cells were activated by resuspending them in lymphocyte culture medium containing either Xvivo15 medium, 5% FBS, 200 U / ml IL2T or Xvivo15 medium, 5% FBS, 20 ng / ml IL21, and 10 ng / ml IL7 to a concentration of individual cells / ml, adding them to a culture dish containing the antibody mixture, and culturing at 37°C and 5% CO2 for 24 hours.
[0234] A certain amount of T cell culture medium was taken, mixed uniformly in a final concentration of 1 mg / ml in Synperonic F108, heated to 37°C in a water bath, and non-infectious reagents were added. Then, the cell culture dishes necessary for the experiment were prepared. First, 1 mg / ml of anti-human CD3 antibody and 0.5 mg / ml of anti-human CD28 antibody were taken, diluted with PBS buffer at a volume ratio of 1:1000 and mixed uniformly, then diluted with retronectin (1 mg / ml) reagent at a volume ratio of 1:40 and mixed uniformly, spread uniformly in the cell culture dish, and incubated at room temperature for 2 hours. After 2 hours, the mixture was washed with PBS, and the cell culture dish was ready.
[0235] Activated T cells were diluted with the prepared infection reagent, and each lentivirus prepared in Example 1 was added and mixed uniformly at a ratio of MOI=3. Subsequently, the cells were uniformly spread in the cell culture dish and infected with lentiviruses to obtain T cells expressing GPC3-41BB, GPC3-41BB-L6, GPC3-41BB-TL6, GPC3-CD28, GPC3-CD28-L6, GPC3-CD28-TL6, GPC3-41BB-L5, GPC3-41BB-TL5, BCMA-41BB, BCMA-41BB-L6, BCMA-41BB-TL6, CD19-41BB, CD19-41BB-L6, CD19-41BB-TL6, MSLN-41BB, MSLN-41BB-L6, MSLN-41BB-TL6, HER2-41BB, HER2-41BB-L6, and HER2-41BB-TL6, respectively. The cell density after infection was 1 × 10⁻⁶. 6 These cell densities were monitored to maintain a cell count of individual cells / ml. After 14 days, the cell count had increased 10 to 100 times.
[0236] Example 3: Promotion of memory T cell formation by LRP6, shortened LRP6, LRP5, or shortened LRP5 T cells expressing GPC3-41BB, GPC3-41BB-L6, GPC3-41BB-TL6, GPC3-CD28, GPC3-CD28-L6, GPC3-CD28-TL6, GPC3-41BB-L5, GPC3-41BB-TL5, BCMA-41BB, BCMA-41BB-L6, BCMA-41BB-TL6, CD19-41BB, CD19-41BB-L6, CD19-41BB-TL6, MSLN-41BB, MSLN-41BB-L6, MSLN-41BB-TL6, HER2-41BB, HER2-41BB-L6, and HER2-41BB-TL6, respectively, obtained in vitro in a cell culture incubator at 37°C and 5% CO2, were cultured for a total of 9 or 13 days.
[0237] The expression levels of CD3, CD8, CD45RO, CD45RA, CD62L, CCR7, CD95, CD122, CD127, CD27, and CD28 proteins in T cells were measured using BD flow cytometry. The measured protein expression results are shown in Figure 2.
[0238] These results indicate that in T cells expressing GPC3-41BB-L6 or GPC3-41BB-TL6, the proportion of memory stem cell-like T cells (TSCMs) and central memory T cells (TCMs) in the total cell number was significantly higher than in the control group; in T cells expressing GPC3-CD28-L6 or GPC3-CD28-TL6, the proportion of TSCMs and TCMs in the total cell number was significantly higher than in the control group; and in T cells expressing GPC3-41BB-L5 or GPC3-41BB-TL5, the proportion of TSCMs and TCMs in the total cell number was significantly higher than in the control group. In T cells expressing L6, the proportion of TSCM and TCM in the total number of cells was significantly higher than in the control group. Similarly, in T cells expressing CD19-41BB-L6 or CD19-41BB-TL6, the proportion of TSCM and TCM in the total number of cells was significantly higher than in the control group. In T cells expressing MSLN-41BB-L6 or MSLN-41BB-TL6, the proportion of TSCM and TCM in the total number of cells was significantly higher than in the control group. In T cells expressing HER2-41BB-L6 or HER2-41BB-TL6, the proportion of TSCM and TCM in the total number of cells was also significantly higher than in the control group.
[0239] Example 4: Differentiation of LRP6 or its shortened suppressor Treg cells T cells expressing GPC3-41BB and GPC3-41BB-L6, respectively, obtained in vitro in a cell culture incubator at 37°C and 5% CO2, were cultured for a total of 9 or 12 days. The expression of CD3, CD4, CD25, CD127, and FoxP3 proteins in the T cells was measured by BD flow cytometry, and the measured protein expression results are shown in Figure 3. According to the results, in T cells expressing GPC3-41BB-L6, CD4 + The study showed that the proportion of regulatory T cells (Tregs) within the T cell population was significantly lower than that of GPC3-41BB-expressing T cells in the control group.
[0240] Example 5: Promotion of tumor antigen-induced specific CAR-T cell proliferation by LRP6, shortened LRP6, LRP5, or shortened LRP5. T cells expressing GPC3-41BB, GPC3-41BB-L6, or GPC3-41BB-TL6 obtained in Example 2 were co-cultured with irradiated Huh7 or HepG2 cells (purchased from the Chinese Academy of Sciences (Shanghai, China) cell bank) in a 1:1 cell ratio in Xvivo15 medium, and Huh7 or HepG2 cells were stimulated three times, with each time being counted by trypan blue staining, and supplemental irradiation was performed once more every 5 days. T cells expressing HER2-41BB, HER2-41BB-L6, or HER2-41BB-TL6 were co-cultured with irradiated SKOV3 cells (purchased from the Chinese Academy of Sciences (Shanghai, China) cell bank) in a 1:1 cell ratio in Xvivo15 medium, with supplemental irradiation performed once every 5 days, and SKOV3 cells stimulated three times, with trypan blue staining counting each time. The cell proliferation patterns of each group were as shown in Figure 4. These results clearly show that the proliferation factor of T cells expressing GPC3-41BB-L6 or GPC3-41BB-TL6 was higher than that of the control group (T cells expressing GPC3-41BB), the proliferation factor of T cells expressing GPC3-41BB-L5 or GPC3-41BB-TL5 was higher than that of the control group, and the proliferation factor of T cells expressing HER2-41BB-L6 or HER2-41BB-TL6 was also significantly higher than that of the control group (T cells expressing HER2-41BB).
[0241] Example 6: Promotion of CAR-T cell in vivo proliferation and cytokine release by LRP6 or its shortened form. In NSG mice (purchased from Beijing baiaosaitu gene Biotechnology), Huh7 cells were administered (1 × 10⁻¹⁰). 7 (1 per mouse) Subcutaneous injection was administered, and 14 days later, the tumor volume in mice was approximately 100 mm². 3 The measurement was performed as follows. At this time, the mice were divided into four groups of 6 mice each, and these were the T cell group, the GPC3-41BB group, the GPC3-41BB-L6 group, and the GPC3-41BB-TL6 group. Then, cells were injected into each group's tail vein (i.e., one group each was injected with unmodified T cells, T cells expressing GPC3-41BB, T cells expressing GPC3-41BB-L6, and T cells expressing GPC3-41BB-TL6), with a dose of 3 × 10⁻¹⁴ 6 The mice were injected (at a dose of one per mouse), and 50 μl of blood was collected from the tail of each mouse on day 8. Human CD8 and CD4 protein expression was measured in each group by BD flow cytometry. The results are shown in Figure 5A. From the results in Figure 5A, it was found that the proportion of cells expressing CD8 and CD4 proteins in the total number of cells was significantly higher in the GPC3-41BB-L6 or GPC3-41BB-TL6 groups than in the other control groups.
[0242] In NSG mice (purchased from Beijing baiaosaitu gene Biotechnology), Huh7 cells were administered (1 × 10⁻¹⁰). 7 (1 per mouse) Subcutaneous injection was administered, and 14 days later, the tumor volume in mice was approximately 100 mm². 3 This was measured as follows. At this time, the mice were divided into 5 groups of 6 mice each, and these were the T cell group, the GPC3-41BB group and the GPC3-41BB-L6 group. Then, T cells were injected into the T cell group from the tail vein (i.e., one group each was injected with unmodified T cells, with a dose of 2 × 10⁻¹⁰⁶. 6 (The number was one / animal), and T cells expressing GPC3-41BB were selected from the GPC3-41BB group (the dose was 8 × 10⁶). 5(It was one individual / animal), and T cells expressing GPC3-41BB-L6 were given to the GPC3-41BB-L6 group (dose was 3 × 10⁶). 5 pieces / fish, 8×10 5 individual / animal or 2 x 10 6 The mice were injected (individually per mouse), and 50 μl of blood was collected from the tail on day 8. The expression of human IL-2, IL4, IL6, IL10, TNF-α, and IFNγ cytokines was measured in each group by BD flow cytometry. The results are shown in Figure 5B. From the results in Figure 5B, it was found that the expression of IFNγ cytokines was significantly higher in the GPC3-41BB-L6 group than in the other control groups.
[0243] Example 7: Enhancement of CAR-T cell antitumor effect by LRP6 or its shortened form. NSG mice (purchased from Beijing Baiaosaitu Gene Biotechnology) were treated with Huh7 cells (at a dose of 1 × 10⁻¹⁶). 7 Subcutaneous inoculation (individual doses per mouse) was administered, and 14 days later, the mouse tumor volume was approximately 100 mm². 3 This was measured as follows. At this time, the mice were divided into four groups of 8 mice each, which were the T cell group, the GPC3-41BB group and the GPC3-41BB-L6 group. Then, T cells were injected into the T cell group from the tail vein (i.e., one group each was injected with unmodified T cells, with a dose of 8 × 10⁻¹⁴ 5 (The number was one / animal), and T cells expressing GPC3-41BB were selected from the GPC3-41BB group (the dose was 8 × 10⁶). 5 (It was one individual / animal), and T cells expressing GPC3-41BB-L6 were given to the GPC3-41BB-L6 group (dose was 3 × 10⁶). 5 individual / animal or 8 x 10 5 They were injected (individually / individually).
[0244] Tumor volume size was measured and mouse mortality was recorded every Monday and Thursday. The results are shown in Figure 6. These results showed that both the antitumor effect and mouse survival rate were approximately three times higher in the GPC3-41BB-L6 group than in the other control groups.
[0245] Example 8 Long-term Survival of LRP6 or Its Truncated Form Promoting CAR-T Cells in Vivo and Prevention of Tumor Recurrence For NSG mice (purchased from Beijing Baiaosaitu Gene Biotechnology Company), Huh7 cells were subcutaneously inoculated (at a dose of 1×10 7 cells / mouse), and 14 days later, the mouse tumor volume was measured to be approximately 100 mm 3 At this time, the mice were divided into 3 groups with 9 mice in each group, namely the T cell group, the GPC3-41BB group, and the GPC3-41BB-L6 group. Then, T cells (at a dose of 2×10 6 cells / mouse) were injected into the T cell group via the tail vein, T cells expressing GPC3-41BB (at a dose of 2×10 6 cells / mouse) were injected into the GPC3-41BB group, and T cells expressing GPC3-41BB-L6 (at a dose of 2×10 6 cells / mouse) were injected into the GPC3-41BB-L6 group.
[0246] 85 days after the tumor completely disappeared, Huh7 cells (at a dose of 3×10 7 cells / mouse) were subcutaneously inoculated into NSG mice again. On the 99th day, 50 μl of blood was collected from the tails of the mice, and the expression of human CD8, CD4, and CD3 proteins in each group was measured by BD flow cytometry. On the 120th day, the bone marrow of the mice was taken out, and the expression of human CD8, CD4, and CD3 proteins in each group was measured by BD flow cytometry.
[0247] The results were as shown in Figure 7. Consequently, the proportion of cells expressing CD8 or CD4 protein in peripheral blood and the proportion of cells expressing CD3 protein in bone marrow were both significantly higher in the GPC3-41BB-L6 group than in the GPC3-41BB group. Furthermore, the GPC3-41BB-L6 mice were unable to form tumors even after being reinoculated with tumor cells. This indicates that LRP6 or its truncated form promotes the long-term survival of CAR-T cells in vivo and offers advantages in preventing tumor recurrence.
[0248] Although a detailed explanation has been provided above by interpretation or illustration, this does not limit the scope of the attached claims. It will be clear to those skilled in the art that there are various modifications to the embodiments described herein, and these fall within the scope of the attached claims and applicable embodiments.
Claims
1. increasing the expression level of low density lipoprotein receptor-related protein or a functional fragment thereof in immune cells; the low-density lipoprotein receptor-related protein is low-density lipoprotein receptor-related protein 6 or low-density lipoprotein receptor-related protein 5; the functional fragment of the low density lipoprotein receptor-related protein comprises an intracellular domain of the low density lipoprotein receptor-related protein, The immune cells further express chimeric antigen receptors (CARs) An ex vivo method, Methods for promoting immune cell proliferation, promoting memory immune cell production and / or inhibiting immune cell differentiation.
2. The method is used to suppress differentiation of immune cells into regulatory T cells (Tregs). The method of claim 1.
3. increasing the expression level of low density lipoprotein receptor-related protein or a functional fragment thereof in immune cells; the low-density lipoprotein receptor-related protein is low-density lipoprotein receptor-related protein 6 or low-density lipoprotein receptor-related protein 5; the functional fragment of the low density lipoprotein receptor-related protein comprises an intracellular domain of the low density lipoprotein receptor-related protein, The immune cells further express chimeric antigen receptors (CARs) An ex vivo method, A method for increasing cytokine release by immune cells.
4. The cytokines include interleukins, interferons and / or tumor necrosis factors. The method of claim 3.
5. The immune cells include lymphocytes. The method according to any one of claims 1 to 4.
6. The immune cells include T cells. The method according to any one of claims 1 to 5.
7. The T cells include memory stem cell-like T cells (TSCM) and / or central memory T cells (TCM); The method of claim 6.
8. The CAR contains an intracellular region comprising a signaling domain and / or a costimulatory domain. The method according to any one of claims 1 to 7.
9. The signaling domain comprises a portion selected from the group consisting of a CD3 zeta signaling domain, a CD3 delta signaling domain, and a CD3 epsilon signaling domain; The method of claim 8.
10. The method of any one of claims 8 to 9, wherein the signaling domain comprises the amino acid sequence represented by SEQ ID NO:
18.
11. The costimulatory domain comprises a portion selected from the group consisting of a CD27 costimulatory domain, a CD28 costimulatory domain, and a 4-1BB costimulatory domain. The method according to any one of claims 8 to 10.
12. The costimulatory domain contains an amino acid sequence represented by any one of SEQ ID NO: 14 and SEQ ID NO:
16. The method according to any one of claims 8 to 11.
13. The CAR comprises a hinge region. The method according to any one of claims 8 to 12.
14. The hinge region comprises a portion selected from the group consisting of an IgG4 hinge region, an IgG1 hinge region, and a CD8 hinge region. The method of claim 13.
15. The hinge region comprises an amino acid sequence represented by SEQ ID NO:
31. The method according to any one of claims 13 to 14.
16. The CAR comprises a transmembrane domain. The method according to any one of claims 8 to 15.
17. The transmembrane domain comprises a portion selected from the group consisting of a CD8 transmembrane domain, a CD28 transmembrane domain, and / or a CD24 transmembrane domain. The method of claim 16.
18. The transmembrane domain comprises an amino acid sequence represented by SEQ ID NO:
33. The method according to any one of claims 16 to 17.
19. The CAR comprises a targeting moiety. The method according to any one of claims 8 to 18.
20. The targeting moiety comprises an ScFv.
20. The method of claim 19.
21. The targeting moiety specifically binds and / or recognizes a tumor antigen; The method according to any one of claims 19 to 20.
22. the targeting moiety specifically binds to and / or recognizes a target selected from the group consisting of a B-lymphocyte surface antigen, a TNF family member, a HER family member, and a GPC family member; The method according to any one of claims 19 to 21.
23. the targeting moiety specifically binds to and / or recognizes a target selected from the group consisting of CD19, BCMA, HER2, Mesothelin and GPC3; 23. The method according to any one of claims 19 to 22.
24. the targeting moiety is an antibody or antigen-binding fragment thereof that specifically binds to and / or recognizes CD19, BCMA, HER2, Mesothelin or GPC3, the antibody or antigen-binding fragment thereof comprising a light chain variable region comprising LCDR1-LCDR3 and a heavy chain variable region comprising HCDR1-HCDR3, the antibody or antigen-binding fragment thereof that specifically binds to CD19 comprises an LCDR1 comprising the amino acid sequence represented by SEQ ID NO: 46, an LCDR2 comprising the amino acid sequence represented by SEQ ID NO: 47, an LCDR3 comprising the amino acid sequence represented by SEQ ID NO: 48, an HCDR1 comprising the amino acid sequence represented by SEQ ID NO: 43, an HCDR2 comprising the amino acid sequence represented by SEQ ID NO: 44, and an HCDR3 comprising the amino acid sequence represented by SEQ ID NO: 45; The antibody or antigen-binding fragment thereof that specifically binds to BCMA comprises an LCDR1 comprising an amino acid sequence represented by SEQ ID NO: 54, an LCDR2 comprising an amino acid sequence represented by SEQ ID NO: 55, an LCDR3 comprising an amino acid sequence represented by SEQ ID NO: 56, an HCDR1 comprising an amino acid sequence represented by SEQ ID NO: 51, an HCDR2 comprising an amino acid sequence represented by SEQ ID NO: 52, and an HCDR3 comprising an amino acid sequence represented by SEQ ID NO: 53; The antibody or antigen-binding fragment thereof that specifically binds to HER2 comprises an LCDR1 containing an amino acid sequence represented by SEQ ID NO: 70, an LCDR2 containing an amino acid sequence represented by SEQ ID NO: 71, an LCDR3 containing an amino acid sequence represented by SEQ ID NO: 72, an HCDR1 containing an amino acid sequence represented by SEQ ID NO: 67, an HCDR2 containing an amino acid sequence represented by SEQ ID NO: 68, and an HCDR3 containing an amino acid sequence represented by SEQ ID NO: 69; The antibody or antigen-binding fragment thereof that specifically binds to mesothelin comprises an LCDR1 containing an amino acid sequence represented by SEQ ID NO: 62, an LCDR2 containing an amino acid sequence represented by SEQ ID NO: 63, an LCDR3 containing an amino acid sequence represented by SEQ ID NO: 64, an HCDR1 containing an amino acid sequence represented by SEQ ID NO: 59, an HCDR2 containing an amino acid sequence represented by SEQ ID NO: 60, and an HCDR3 containing an amino acid sequence represented by SEQ ID NO: 61; The antibody or antigen-binding fragment thereof that specifically binds to GPC3 comprises an LCDR1 having an amino acid sequence represented by SEQ ID NO: 38, an LCDR2 having an amino acid sequence represented by SEQ ID NO: 39, an LCDR3 having an amino acid sequence represented by SEQ ID NO: 40, an HCDR1 having an amino acid sequence represented by SEQ ID NO: 35, an HCDR2 having an amino acid sequence represented by SEQ ID NO: 36, and an HCDR3 having an amino acid sequence represented by SEQ ID NO:
37. The method according to any one of claims 19 to 23.
25. The method further comprises the steps of: + T lymphocytes, CD8 + T lymphocytes, CD4 + The method includes a step of isolating and obtaining T lymphocytes or regulatory T cells.
25. The method according to any one of claims 1 to 24.
26. The method may further comprise the step of adding one or more T cell stimulatory factors to the isolated PBMCs. The method of claim 25.
27. The T cell stimulatory factor is selected from the group consisting of a B lymphocyte surface antigen antibody, a TNF antibody, an intracellular polyester, and an antibiotic; 27. The method of claim 26.
28. The T cell stimulatory factor is selected from the group consisting of CD3 antibody, CD28 antibody, 4-1BB antibody, CD80 antibody, CD86 antibody, PHA, PMA and ionomycin; 28. The method according to any one of claims 26 to 27.
29. The method may further comprise the step of administering to the isolated PBMCs one or more cytokine agents.
29. The method according to any one of claims 26 to 28.
30. The cytokine agent comprises an interleukin.
30. The method of claim 29.
31. The interleukin comprises one or more interleukins selected from the group consisting of IL2, IL21, IL7 and IL15. The method of claim 30.
32. The low density lipoprotein receptor-related protein or a functional fragment thereof is of human origin.
32. The method according to any one of claims 1 to 31.
33. The functional fragment of the low density lipoprotein receptor-related protein 6 comprises the transmembrane and intracellular regions of the low density lipoprotein receptor-related protein 6, and / or the functional fragment of the low density lipoprotein receptor-related protein 5 comprises the transmembrane and intracellular regions of the low density lipoprotein receptor-related protein 5.
33. The method according to any one of claims 1 to 32.
34. The low density lipoprotein receptor-related protein or a functional fragment thereof comprises an amino acid sequence represented by any one of SEQ ID NOs: 22, 24, 26 and 28; 34. The method according to any one of claims 1 to 33.
35. The method of any one of claims 1 to 34, wherein the nucleic acid molecule encoding the low density lipoprotein receptor-related protein or a functional fragment thereof comprises a nucleic acid sequence represented by any one of SEQ ID NOs: 21, 23, 25 and 27.
36. The genetic modification enhances the expression of low-density lipoprotein receptor-related protein or a functional fragment thereof in immune cells; the low-density lipoprotein receptor-related protein is low-density lipoprotein receptor-related protein 6 or low-density lipoprotein receptor-related protein 5; the functional fragment of the low density lipoprotein receptor-related protein comprises the intracellular domain of the low density lipoprotein receptor-related protein, The genetically modified immune cells further express a chimeric antigen receptor (CAR). Genetically modified immune cells.
37. The genetically modified immune cells include lymphoid cells. The immune cell of claim 36.
38. The genetically modified immune cells include genetically modified T cells. The immune cell according to any one of claims 36 to 37.
39. The genetically modified immune cells include genetically modified memory stem cell-like T cells (TSCM) and / or genetically modified central memory T cells (TCM); The immune cell according to any one of claims 36 to 38.
40. The CAR contains an intracellular domain consisting of a signaling domain and / or a costimulatory domain. The immune cell according to any one of claims 36 to 39.
41. The signaling domain comprises a portion selected from the group consisting of a CD3 zeta signaling domain, a CD3 delta signaling domain, and a CD3 epsilon signaling domain; The immune cell of claim 40.
42. The immune cell of any one of claims 40 to 41, wherein the signaling domain comprises an amino acid sequence represented by SEQ ID NO:
18.
43. The costimulatory domain comprises a portion selected from the group consisting of a CD27 costimulatory domain, a CD28 costimulatory domain, and a 4-1BB costimulatory domain. The immune cell according to any one of claims 40 to 42.
44. The costimulatory domain contains an amino acid sequence represented by any one of SEQ ID NO: 14 and SEQ ID NO:
16. The immune cell according to any one of claims 40 to 43.
45. The CAR comprises a hinge region. An immune cell according to any one of claims 40 to 44.
46. The hinge region comprises a portion selected from the group consisting of an IgG4 hinge region, an IgG1 hinge region, and a CD8 hinge region.
46. The immune cell of claim 45.
47. The hinge region comprises an amino acid sequence represented by SEQ ID NO:
31. The immune cell according to any one of claims 45 to 46.
48. The CAR comprises a transmembrane domain. The immune cell according to any one of claims 36 to 47.
49. The transmembrane domain comprises a portion selected from the group consisting of a CD8 transmembrane domain, a CD28 transmembrane domain, and / or a CD24 transmembrane domain.
49. The immune cell of claim 48.
50. The transmembrane domain comprises an amino acid sequence represented by SEQ ID NO:
33.
50. The immune cell according to any one of claims 48 to 49.
51. The CAR comprises a targeting moiety. The immune cell according to any one of claims 36 to 50.
52. The targeting moiety comprises an ScFv.
52. The immune cell of claim 51.
53. The targeting moiety specifically binds and / or recognizes a tumor antigen; An immune cell according to any one of claims 51 to 52.
54. the targeting moiety specifically binds to and / or recognizes a target selected from the group consisting of a B-lymphocyte surface antigen, a TNF family member, a HER family member, and a GPC family member; An immune cell according to any one of claims 51 to 53.
55. the targeting moiety specifically binds to and / or recognizes a target selected from the group consisting of CD19, BCMA, HER2, Mesothelin and GPC3; An immune cell according to any one of claims 51 to 54.
56. the targeting moiety is an antibody or antigen-binding fragment thereof that specifically binds to and / or recognizes CD19, BCMA, HER2, Mesothelin or GPC3, the antibody or antigen-binding fragment thereof comprising a light chain variable region comprising LCDR1-LCDR3 and a heavy chain variable region comprising HCDR1-HCDR3, the antibody or antigen-binding fragment thereof that specifically binds to CD19 comprises an LCDR1 comprising the amino acid sequence represented by SEQ ID NO: 46, an LCDR2 comprising the amino acid sequence represented by SEQ ID NO: 47, an LCDR3 comprising the amino acid sequence represented by SEQ ID NO: 48, an HCDR1 comprising the amino acid sequence represented by SEQ ID NO: 43, an HCDR2 comprising the amino acid sequence represented by SEQ ID NO: 44, and an HCDR3 comprising the amino acid sequence represented by SEQ ID NO: 45; The antibody or antigen-binding fragment thereof that specifically binds to BCMA comprises an LCDR1 comprising an amino acid sequence represented by SEQ ID NO: 54, an LCDR2 comprising an amino acid sequence represented by SEQ ID NO: 55, an LCDR3 comprising an amino acid sequence represented by SEQ ID NO: 56, an HCDR1 comprising an amino acid sequence represented by SEQ ID NO: 51, an HCDR2 comprising an amino acid sequence represented by SEQ ID NO: 52, and an HCDR3 comprising an amino acid sequence represented by SEQ ID NO: 53; The antibody or antigen-binding fragment thereof that specifically binds to HER2 comprises an LCDR1 containing an amino acid sequence represented by SEQ ID NO: 70, an LCDR2 containing an amino acid sequence represented by SEQ ID NO: 71, an LCDR3 containing an amino acid sequence represented by SEQ ID NO: 72, an HCDR1 containing an amino acid sequence represented by SEQ ID NO: 67, an HCDR2 containing an amino acid sequence represented by SEQ ID NO: 68, and an HCDR3 containing an amino acid sequence represented by SEQ ID NO: 69; The antibody or antigen-binding fragment thereof that specifically binds to mesothelin comprises an LCDR1 containing an amino acid sequence represented by SEQ ID NO: 62, an LCDR2 containing an amino acid sequence represented by SEQ ID NO: 63, an LCDR3 containing an amino acid sequence represented by SEQ ID NO: 64, an HCDR1 containing an amino acid sequence represented by SEQ ID NO: 59, an HCDR2 containing an amino acid sequence represented by SEQ ID NO: 60, and an HCDR3 containing an amino acid sequence represented by SEQ ID NO: 61; The antibody or antigen-binding fragment thereof that specifically binds to GPC3 comprises an LCDR1 having an amino acid sequence represented by SEQ ID NO: 38, an LCDR2 having an amino acid sequence represented by SEQ ID NO: 39, an LCDR3 having an amino acid sequence represented by SEQ ID NO: 40, an HCDR1 having an amino acid sequence represented by SEQ ID NO: 35, an HCDR2 having an amino acid sequence represented by SEQ ID NO: 36, and an HCDR3 having an amino acid sequence represented by SEQ ID NO:
37. An immune cell according to any one of claims 51 to 55.
57. The low density lipoprotein receptor-related protein or a functional fragment thereof is of human origin. The immune cell according to any one of claims 36 to 56.
58. The functional fragment of the low density lipoprotein receptor-related protein 6 comprises the transmembrane and intracellular regions of the low density lipoprotein receptor-related protein 6, and / or the functional fragment of the low density lipoprotein receptor-related protein 5 comprises the transmembrane and intracellular regions of the low density lipoprotein receptor-related protein 5. An immune cell according to any one of claims 36 to 57.
59. The low density lipoprotein receptor-related protein or a functional fragment thereof comprises an amino acid sequence represented by any one of SEQ ID NOs: 22, 24, 26 and 28; An immune cell according to any one of claims 36 to 58.
60. The nucleic acid molecule encoding the low density lipoprotein receptor-related protein or a functional fragment thereof comprises a nucleic acid sequence represented by any one of SEQ ID NOs: 21, 23, 25 and 27. An immune cell according to any one of claims 36 to 59.
61. The genetically modified immune cell according to any one of claims 36 to 60, composition.
62. Further comprising a pharma- ceutically acceptable carrier, 62. The composition of claim 61.
63. For use in the treatment and / or prevention of tumors, 63. The composition of any one of claims 61 to 62.
64. The tumor is selected from the group consisting of liver cancer, lung cancer, leukemia and mesothelioma; 64. The composition of claim 63.
65. The method includes a step of introducing a vector that increases the expression level of the low-density lipoprotein receptor-related protein or a functional fragment thereof into an immune cell, the low-density lipoprotein receptor-related protein is low-density lipoprotein receptor-related protein 6 or low-density lipoprotein receptor-related protein 5; the functional fragment of the low density lipoprotein receptor-related protein comprises the intracellular domain of the low density lipoprotein receptor-related protein, the genetically modified immune cells express a chimeric antigen receptor (CAR); An ex vivo method, A method for preparing a genetically modified immune cell according to any one of claims 36 to 60.
66. The vector is selected from the group consisting of a retroviral vector, a lentiviral vector and a transposon plasmid; 66. The method of claim 65.
67. The low density lipoprotein receptor-related protein or a functional fragment thereof comprises an amino acid sequence represented by any one of SEQ ID NOs: 22, 24, 26 and 28; 67. The method according to any one of claims 65 to 66.
68. The genetically modified immune cells include lymphoid cells.
68. The method according to any one of claims 65 to 67.
